<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Cell Int</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Cell Int</journal-id><journal-title-group><journal-title>Cancer Cell International</journal-title></journal-title-group><issn pub-type="epub">1475-2867</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40405281</article-id><article-id pub-id-type="pmc">PMC12100833</article-id>
<article-id pub-id-type="publisher-id">3828</article-id><article-id pub-id-type="doi">10.1186/s12935-025-03828-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Role of hesperidin/hesperetin against chemotherapy-induced cardiotoxicity: a systematic review of non-clinical studies</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Shaernejad</surname><given-names>Sina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Nosrat</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Baeeri</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hashemi Goradel</surname><given-names>Nasser</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>SeyedSadeghi</surname><given-names>Mirsalim</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Akbariani</surname><given-names>Mostafa</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9594-5522</contrib-id><name><surname>Arabzadeh</surname><given-names>AmirAhmad</given-names></name><address><email>amir_medico@yahoo.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2854-9567</contrib-id><name><surname>Rahimifard</surname><given-names>Mahban</given-names></name><address><email>mahban.rahimifard@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7863-6821</contrib-id><name><surname>Haghi-Aminjan</surname><given-names>Hamed</given-names></name><address><email>hamedhaghi.a@gmail.com</email><email>h-haghi@tums.ac.ir</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04n4dcv16</institution-id><institution-id institution-id-type="GRID">grid.411426.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0611 7226</institution-id><institution>Students Research Committee, School of Medicine, </institution><institution>Ardabil University of Medical Sciences, </institution></institution-wrap>Ardabil, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01c4pz451</institution-id><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution>Toxicology and Diseases Specialty Group, Pharmaceutical Sciences Research Center (PSRC), </institution><institution>Tehran University of Medical Sciences (TUMS), </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0037djy87</institution-id><institution-id institution-id-type="GRID">grid.449862.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0518 4224</institution-id><institution>Department of Medical Biotechnology, </institution><institution>Maragheh University of Medical Sciences, </institution></institution-wrap>Maragheh, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04n4dcv16</institution-id><institution-id institution-id-type="GRID">grid.411426.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0611 7226</institution-id><institution>Department of Surgery, School of Medicine, </institution><institution>Ardabil University of Medical Sciences, </institution></institution-wrap>Ardabil, Iran </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01c4pz451</institution-id><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution>Department of Pharmacology and Toxicology, Faculty of Pharmacy, </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>186</elocation-id><history><date date-type="received"><day>20</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>11</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Despite the undeniable role of chemotherapeutics in cancer treatment, their administration may be associated with various side effects. Cardiac injury is among the most crucial side effects related to the induction of chemotherapeutic agents. Since the heart is a vital organ, cardiotoxicity often prevents clinicians from continuing chemotherapy. Hesperidin and hesperetin, flavonoids derived from citrus fruits, possess several pharmaceutical properties. This study firstly explores the cardioprotective effects of hesperidin and hesperetin against chemotherapy-induced cardiotoxicity mechanisms, emphasizing their potential as adjunctive therapies. Key literature gaps are identified, and further mechanistic studies will be proposed. The findings underscore the translational potential of these flavonoids, advocating for rigorous preclinical optimization and clinical trials to validate their efficacy and safety. This review lays a foundation for integrating natural compounds into cardioprotective strategies in oncology. A systematic search was conducted in databases (PubMed, Scopus, ISI) until May 2025, according to PRISMA principles. The search terms were chosen according to our research objective and queried in the title and abstract. Following the screening of 82 papers, twelve articles were selected based on our inclusion and exclusion criteria. Based on the evaluated results, chemotherapy adversely affects cardiac tissue, leading to elevated risks of morbidity and mortality. Co-administration of hesperidin and hesperetin with chemotherapy prevents heart injury and preserves cardiac function, maintaining it almost like a normal heart. The protective role of hesperidin and hesperetin is based on their ability to fight free radicals, reduce inflammation, and stop cell death. Nonclinical investigations indicate that hesperidin and hesperetin ameliorate chemotherapy-induced cardiotoxicity. Nonetheless, they may influence the efficacy of anticancer medications, which primarily function by elevating oxidants, inflammation, and apoptosis. This indicates that meticulously designed trials are necessary to evaluate the efficacy and safety of this combination along with the synergistic potential of them in preventing chemotherapy-induced cardiotoxicity while maintaining anticancer effectiveness.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Doxorubicin</kwd><kwd>Paclitaxel</kwd><kwd>Cisplatin</kwd><kwd>Cyclophosphamide</kwd><kwd>Epirubicin</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">According to previous studies, after cardiovascular disorders, cancer holds the second position as the leading cause of early death globally. Recent studies reveal a significant increase in cancer cases, potentially positioning it as the leading cause of early mortality worldwide [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The World Health Organization (WHO) characterizes cancer as a diverse collection of diseases that may arise in almost any organ or tissue when abnormal cells proliferate uncontrollably, extend beyond their usual boundaries to invade neighboring regions, and/or spread to other organs [<xref ref-type="bibr" rid="CR3">3</xref>]. Cancer remains one of the leading causes of morbidity and mortality worldwide. According to the latest data from GLOBOCAN 2022, an initiative by the International Agency for Research on Cancer (IARC), there were close to 20&#x000a0;million new cancer cases and 10.0&#x000a0;million cancer-related deaths globally in 2022 [<xref ref-type="bibr" rid="CR4">4</xref>]. Based on a previous study, chemotherapy-related cardiac dysfunction in cancer patients was 63.21 per 1000 person&#x02010;years [<xref ref-type="bibr" rid="CR5">5</xref>]. There are many ways to treat cancer, from the more common ones like surgery, chemotherapy, and radiation therapy to more cutting-edge ones like targeted therapy, ablation therapy, stem cell therapy, natural antioxidants, nanomedicine, sonodynamic therapy, chemodynamic therapy, radionics, and therapies based on ferroptosis [<xref ref-type="bibr" rid="CR6">6</xref>]. Despite the advancement of novel cancer treatment methodologies, conventional approaches remain the predominant modalities employed globally [<xref ref-type="bibr" rid="CR7">7</xref>]. Chemotherapy is a commonly utilized method in cancer treatment, noted for its effectiveness in suppressing tumor cells by targeting those with excessively high rates of division and proliferation [<xref ref-type="bibr" rid="CR8">8</xref>]. However, it can also cause significant adverse effects such as nausea and vomiting, alopecia, cardiotoxicity, chemotherapy-induced peripheral neuropathy, infertility, diarrhea, harm to healthy cells, and organ damage [<xref ref-type="bibr" rid="CR9">9</xref>]. The heart functions as the engine of the human body; hence, cardiac toxicity represents a significant adverse effect, with any impairment in cardiac function potentially resulting in diminished quality of life or, in extreme cases, mortality. Cardiotoxic consequences that may occur after chemotherapy include hypertension, dilated cardiomyopathy, arrhythmias, myocardial infarctions, and sudden death [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par3">Unfortunately, the exact way that chemotherapy hurts the heart is still not fully understood. However, research shows that the formation of free radicals results in oxidative stress, which kills heart cells [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Since there isn&#x02019;t a strong rule for dealing with cardiotoxicity caused by chemotherapy, finding drugs that protect the heart may be crucial for minimizing damage to it during cancer treatment [<xref ref-type="bibr" rid="CR13">13</xref>]. Hesperidin is a bioflavonoid abundantly present in various citrus fruits, including sweet oranges, mandarins, limes, grapefruits, and lemons [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Hesperetin is the aglycone derivative of hesperidin [<xref ref-type="bibr" rid="CR17">17</xref>]. Both hesperidin and hesperetin have diverse pharmacological qualities, including antioxidant, anticancer, and anti-inflammatory effects [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. Numerous studies have demonstrated the advantageous effects of hesperidin and hesperetin consumption in diseases such as diabetes [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], rheumatoid arthritis [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], cancers [<xref ref-type="bibr" rid="CR25">25</xref>], and several neurological conditions, such as Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par4">Finally, hesperidin and hesperetin are relevant to the manuscript&#x02019;s focus due to their well-established bioactive properties, mechanistic alignment with the pathophysiology of chemotherapy-induced cardiotoxicity, and the availability of non-clinical evidence supporting their cardioprotective effects. A systematic review of these compounds can provide valuable insights and pave the way for future clinical studies. This in-depth review looks at whether hesperidin and hesperetin can protect the heart from the damage caused by chemotherapy, since they each play a different role in heart damage. This study conducted a thorough literature review on the functions of hesperidin and hesperetin in chemotherapy-induced cardiotoxicity. It was also explained how chemotherapeutic medications hurt the heart and what roles hesperidin and hesperetin play in this.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Search strategy and information sources</title><p id="Par5">This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline [<xref ref-type="bibr" rid="CR27">27</xref>]. A comprehensive literature search was conducted to obtain all relevant studies on &#x0201c;the role of hesperidin/hesperetin on chemotherapy-induced cardiotoxicity&#x0201d; in both medical subject heading (MeSH) or advanced in the electronic databases PubMed/Medline, Scopus, and Web of Science (ISI) using the keywords including; (Hesperidin OR Hesperetin) AND (Heart OR Myocardium OR Myocardial&#x0201d; OR &#x0201c;Cardiac Toxicity&#x0201d; OR &#x0201c;Cardiac Toxicities&#x0201d; OR Cardiomyopathy OR Myocyte OR Cardiopathic OR Cardiopathy OR Cardiotoxicity OR Cardiotoxicities OR Cardiomyocyte OR Cardiac) AND (Bevacizumab OR Avastin OR Mvasi OR Daunorubicin OR Adriamycin OR Doxorubicin OR Idarubicin OR Cisplatin OR Carboplatin OR Paraplatin OR Bleomycin OR Carmustine OR Cyclophosphamide OR Cytophosphane OR Melphalan OR Etoposide OR Etopophos OR Mitomycin OR Vinblastine OR Vinorelbine OR Navelbine OR Paclitaxel OR Taxol OR Docetaxel OR Taxotere OR Procarbazine OR Asparlas OR Epirubicin OR Amethopterin OR Mustine OR Embikhin OR Mechlorethamine OR Oxaliplatin OR Eloxatin OR Cytarabine OR Cytosine OR Fluorouracil OR Adrucil OR Capecitabine OR Xeloda OR Vincristine OR Sunitinib OR Irinotecan OR Chemotherapy) up to May 2025.</p></sec><sec id="Sec4"><title>Criteria for eligibility and selection of studies</title><p id="Par6">After acquiring and organizing the articles in the reference management software, duplicates were eliminated. Subsequently, two independent evaluators (Sina Shaernejad and Ali Nosrat) conducted a two-phase screening procedure. The initial screening process evaluated the articles by analyzing their titles and abstracts according to their relevance to the objectives of the current study. In the second screening process, we assessed the full-text articles in the concluding phase according to our inclusion and exclusion criteria. For our research, our inclusion criteria included (1) the articles that focused on the role of hesperidin/hesperetin in chemotherapy-induced cardiotoxicity; (2) peer-reviewed articles; (3) articles that had enough data; and (4) articles that didn&#x02019;t have any restrictions on the publication year. The study&#x02019;s exclusion criteria included (a) cardiac hemodynamic data, (b) book chapters, (c) case reports, (d) irrelevant research, (e) letters to the editor, (f) editorials, (g) review articles, (h) posters, and (i) conference papers and abstracts.</p></sec><sec id="Sec5"><title>Data extraction process</title><p id="Par7">Two researchers (Sina Shaernejad and Ali Nosrat) assessed each qualifying study and then gathered the following information: (1) Author&#x02019;s name and publication year; (2) types of models utilized (in-vivo and/or in-vitro); (3) dosage of chemotherapy medications, administration protocol, and method of delivery; (4) effects of chemotherapy agents on cardiac cells and tissues; (5) dosage of hesperidin/hesperetin, administration protocol, and method of administration; and (6) outcomes of concurrent hesperidin/hesperetin and chemotherapy administration.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Literature search and screening</title><p id="Par8">Figure <xref rid="Fig1" ref-type="fig">1</xref> illustrates the procedure for study selection. The elimination process was carried out according to the technique specified in the pervious study [<xref ref-type="bibr" rid="CR28">28</xref>]. A total of 82 articles were obtained by a systematic search of the specified electronic databases until May 2025. Following the removal of duplicate articles (<italic>n</italic>&#x02009;=&#x02009;34), the remaining articles (<italic>n</italic>&#x02009;=&#x02009;48) were assessed according to their titles and abstracts (first screening), resulting in the exclusion of 22 articles. We considered 26 articles suitable for full evaluation, of which 14 articles were removed (8 articles&#x02009;=&#x02009;unrelated, 3 articles&#x02009;=&#x02009;review articles, 2 articles&#x02009;=&#x02009;not founded and 1 article&#x02009;=&#x02009;conference papers). Twelve articles were finally selected for inclusion in this study, adhering to the established criteria for inclusion and exclusion.</p><p id="Par9">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart illustrating the selection procedure employed in the current investigation</p></caption><graphic xlink:href="12935_2025_3828_Fig1_HTML" id="d33e358"/></fig>
</p></sec><sec id="Sec8"><title>Data extraction</title><p id="Par10">Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> present additional data from each article, utilizing the methodologies of Sina Shaernejad and Ali Nosrat. Two researchers independently reviewed and agreed on all potential inconsistencies.</p><p id="Par11">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>The characteristics hesperidin of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Author, year</th><th align="left">Models</th><th align="left">Chemotherapy medications (dosage) &#x00026; Treatment protocol &#x00026; Route of<break/>administration type</th><th align="left">Outcomes of chemotherapy medications on cardiac tissue</th><th align="left">Hesperidin dosage &#x00026; protocol of usage &#x00026; route of administration</th><th align="left">Hesperidin co-administration outcomes</th></tr></thead><tbody><tr><td align="left">Alharbi, F.K., et al.,2023 [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left">In-vivo/ Rat</td><td align="left">Doxorubicin (4&#x000a0;mg/kg b.w) &#x00026; once every week for five consecutive weeks &#x00026; <italic>ip</italic></td><td align="left">&#x02191;Levels of cTn-I, CK-Total, CK-MB, LDH, AST, IFN-&#x003b3;, IL-1&#x003b2;, &#x00026; TNF-&#x003b1;, &#x02193;Activity of GPx, catalase &#x00026; SOD, severe zenker&#x02019;s degenerations, &#x02191;intercellular spaces with interstitial edema, disarray of the cardiomyocytes, abnormal thickened cardiac muscle, severe vacuolizations, severe thickening of the blood vessels wall, &#x02191;collagen fibers formations, excessive extravasated RBCs, &#x02191;infiltration of inflammatory cells</td><td align="left">100&#x000a0;mg/kg b.w/day &#x00026; 5 days in a week up to five consecutive weeks &#x00026; <italic>po</italic></td><td align="left">&#x02193; Levels of Troponin I, CK Total, CK-MB, LDH, AST, IFN-&#x003b3;, IL-1&#x003b2;, &#x00026; TNF-&#x003b1;, &#x02191;Activity of GPx, catalase &#x00026; SOD, normal looking cardiomyocytes, slight blood vessel dilatation, individual extravasated RBCs, mild zenker&#x02019;s degenerations, &#x02193;infiltration of inflammatory cells</td></tr><tr><td align="left">Ali, Y. A., et al.,2023 [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">In-vivo/ Rat</td><td align="left">Paclitaxel (2&#x000a0;mg/kg b.w) &#x00026; twice a week for 6 weeks &#x00026; <italic>ip</italic></td><td align="left">&#x02191;Levels of CK-MB &#x00026; LDH &#x02193;Activity of GPx &#x00026; SOD &#x02191;LPO, &#x02193;GSH content, &#x02191;severe hyalinosis &#x00026; severe leucocytic infiltration</td><td align="left">10&#x000a0;mg/kg b.w &#x00026; twice Weekly &#x00026; <italic>po</italic></td><td align="left">&#x02193;Levels of CK-MB &#x00026; LDH, &#x02191;Activity of GPx &#x00026; SOD, &#x02193; LPO, moderate hyalinosis, absence of leucocytic infiltration</td></tr><tr><td align="left">Oguzturk, H., et al.,2016 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">In-vivo/ Rat</td><td align="left">Cisplatin (7&#x000a0;mg/kg) &#x00026; single injection &#x00026; <italic>ip</italic></td><td align="left">&#x02193;Levels of SOD, GSH, &#x00026; catalase, &#x02191;Levels of TBARS, Esinophilic staining, &#x02191;pyknosis of nuclei cells, hemorrhage &#x00026; cell degeneration</td><td align="left"><p>50&#x000a0;mg/kg/day &#x00026; for 14 consecutives</p><p>days &#x00026; by <italic>po</italic></p></td><td align="left">&#x02191;Levels of SOD, GSH, &#x02193;Levels of TBARS, absence of esinophilic staining, pyknosis of nuclei cells, hemorrhage &#x00026; cell degeneration</td></tr><tr><td align="left">Al-Sefri, H. A., et al.,2020 [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">In-vivo/ Rat</td><td align="left">Doxorubicin (10&#x000a0;mg/Kg b.w) single dose &#x00026; <italic>ip</italic></td><td align="left">&#x02191;Levels of cTn-I, cTn-T, FABP3, MYLK, CK-MB, LDH, AST, BNP, CRP, TNF-&#x003b1;, ox-LDL, &#x00026; MDA, &#x02193;SOD activity, &#x02191;Cell degeneration, hemorrhage &#x00026; vacuolization</td><td align="left">50&#x000a0;mg/kg b.w &#x00026; 30 days &#x00026; <italic>po</italic></td><td align="left">&#x02193;Levels of cTn-I, cTn-T, FABP3, MYLK, CK-MB, AST, BNP, CRP, TNF-&#x003b1;, MDA, &#x02191;SOD activity, Absence of cell degeneration, hemorrhage &#x00026; vacuolization</td></tr><tr><td align="left">Donia, T., et al.,2019 [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">In-vivo/ Rat</td><td align="left">Doxorubicin (4&#x000a0;mg /kg b.w) &#x00026; three times per week for 2 weeks &#x00026; <italic>ip</italic></td><td align="left">&#x02191;Levels of LDH, CK, TG, TC, LDL, MDA, NO, &#x02193;Levels of HDL, GSH, &#x02191;Activity of MPO, catalase, Caspase-3, &#x02193;Activity of AE, &#x00026; PON, Extensive loss of myofibril, &#x02191;infiltration of inflammatory cells, vacuolization, &#x02191;Apoptosis.</td><td align="left">50&#x000a0;mg/kg b.w &#x00026; three times per week for 3 weeks &#x00026; <italic>po</italic></td><td align="left">&#x02193;Levels of LDH, CK, TG, TC, LDL, Heart MDA, NO &#x02191;Levels of HDL, GSH &#x02193;Activity of MPO, catalase, Caspase-3 &#x02191;Activity of AE &#x00026; PON, Well-preserved myocardium, &#x02193;Loss of myofibrils</td></tr><tr><td align="left" rowspan="2">Jia, Y., et al.,2022 [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left" rowspan="2">In-vivo/ mouse</td><td align="left" rowspan="2">Cisplatin (5&#x000a0;mg/kg) &#x00026; two times per week for 1 week &#x00026; <italic>ip</italic></td><td align="left" rowspan="2">&#x02191;Levels of cTnI, CK, LDH, TNF-&#x003b1;, IL6, &#x00026; MDA &#x02193;Levels of SOD, catalase, &#x00026; GSH, upregulation of Bax &#x00026; Caspase-3, downregulation of Bcl-2, &#x02193;Expression of p62 &#x00026; Nrf2, &#x02191;Expression of Keap1, &#x02191;Infiltration of inflammatory cells, Apoptosis &#x00026; cellular edema</td><td align="left">100&#x000a0;mg/kg once a day &#x00026; one week &#x00026; <italic>po</italic></td><td align="left">&#x02193;Levels of cTnI, CK, LDH, TNF-&#x003b1;, IL6 &#x00026; MDA &#x02191;Levels of SOD, catalase, &#x00026; GSH, downregulation of Bax &#x00026; Caspase-3 upregulation of Bcl-2, &#x02191;expression of p62 and Nrf2, &#x02193;expression of Keap1, &#x02193;Infiltration of inflammatory cells, Apoptosis &#x00026; cellular edema</td></tr><tr><td align="left">300&#x000a0;mg/kg once a day &#x00026; one week &#x00026; <italic>po</italic></td><td align="left">&#x02193;Levels of cTnI, CK, LDH, TNF-&#x003b1;, IL6 &#x00026; MDA, &#x02191;Levels of SOD, catalase, &#x00026; GSH downregulation of Bax &#x00026; Caspase-3 upregulation of Bcl-2, &#x02191;expression of p62 and Nrf2, &#x02193;expression of Keap1, &#x02193;Infiltration of inflammatory cells, Apoptosis &#x00026; cellular edema</td></tr><tr><td align="left">Kumar, S., et al.,2011 [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">In-vivo/ Rat</td><td align="left">Cyclophosphamide (200&#x000a0;mg/kg b.w) &#x00026; single dose &#x00026; <italic>ip</italic></td><td align="left">&#x02191;Levels of CK, ALT, AST, LDH, TNF-&#x003b1;, &#x00026; MDA, &#x02193;Levels of SOD, catalase, GPx, GST, &#x00026; GSH.</td><td align="left">100&#x000a0;mg/kg b.w &#x00026; one week &#x00026; <italic>po</italic></td><td align="left">&#x02193;Levels of CK, ALT, AST, LDH, TNF-&#x003b1;, &#x00026; MDA, &#x02191;Levels of SOD, catalase, GPx, GST, &#x00026; GSH</td></tr><tr><td align="left">Shrivastava, M., et al.,2013 [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left">In-vivo/ Rat</td><td align="left">Cyclophosphamide (200&#x000a0;mg/kg b.w) &#x00026; single dose &#x00026; <italic>ip</italic></td><td align="left">&#x02191;Levels of CK, ALT, AST, LDH, &#x00026; MDA.</td><td align="left">100&#x000a0;mg/kg b.w &#x00026; one week &#x00026; <italic>po</italic></td><td align="left">&#x02193;Levels of CK, ALT, AST, LDH, &#x00026; MDA</td></tr><tr><td align="left">Farooq, J., et al.,2024 [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left">In-vivo/ Rat</td><td align="left">5-Fluorouracil (150&#x000a0;mg/kg b.w) &#x00026; single dose &#x00026; <italic>ip</italic></td><td align="left">&#x02191;Levels of CK-MB, CK-NAC, LDH, MPO, MDA, NO, IL-6, IL-8, &#x00026; TNF-&#x003b1;, &#x02193;Levels of SOD, GSH, &#x00026; catalase, severe cardiac cell damage, including necrosis and vacuolar changes in muscle fibers, fragmentation.</td><td align="left">100&#x000a0;mg/kg &#x00026; eight days &#x00026; <italic>po</italic></td><td align="left">&#x02193;Levels of CK-MB, CK-NAC, LDH, MPO, MDA, NO, IL-6, IL-8, &#x00026; TNF-&#x003b1;, &#x02191;Levels of SOD, GSH, &#x00026; catalase, mild hyperemia</td></tr><tr><td align="left">Saad, S., et al.,2020 [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left">In-vivo/ Rat</td><td align="left">Doxorubicin (15&#x000a0;mg/kg) single dose &#x00026; <italic>ip</italic></td><td align="left">&#x02191;Levels of CK-MB, cTn-I, &#x00026; MDA, &#x02193;Levels of catalase, &#x00026; SOD, &#x02191;Activity caspase-3, &#x02193;Heart weight, edema, loss of cellular boundaries, myocardial fibers disorganization, cytoplasmic &#x02191;Vacuolization, &#x00026; lymphocytic infiltration.</td><td align="left">20&#x000a0;mg/kg &#x00026; one week &#x00026; <italic>po</italic></td><td align="left">&#x02193;Levels of CK-MB, cTn-I, &#x00026; MDA &#x02191;Levels of catalase, &#x00026; SOD, &#x02193;Activity caspase-3, &#x02193;Pathological lesions without full reversal.</td></tr></tbody></table><table-wrap-foot><p>&#x02191;, Increase; &#x02193;, Decease; &#x00026;, And; <italic>ip</italic>, Intraperitoneal; <italic>po</italic>, Per os; CK, Creatine kinase; CK-MB, Creatine kinase isoenzyme-MB; LDH, Lactate dehydrogenase; AST, Aspartate aminotransferase; IFN-&#x003b3;, Interferon &#x003b3;; IL-1&#x003b2;, Interleukin 1&#x003b2;; TNF-&#x003b1;, Tumor necrosis factor &#x003b1;; GPx, Glutathione peroxidase; SOD, Superoxide dismutase; LPO: Lipid peroxidation; GSH: Reduced glutathione; TBARS, Thiobarbituric acid reactive substances; cTn-I, Troponins I; cTn-T, Troponins T; FABP3, Fatty acid-binding protein; MYLK, Myosin light-chain kinase I; BNP, B-type Natriuretic Peptide; CRP, C-reactive protein; ox-LDL, Oxidized low-density lipoproteins; MDA, Malondialdehyde; TG, Triglycerides; TC, Total cholesterol; LDL, low-density lipoproteins; NO, Nitric oxide; HDL, High density lipoprotein; GSH, Glutathione; MPO, Myeloperoxidase; AE, Arylesterase; PON, Paraoxonase; IL-6, Interleukin 6; Bcl-2, Anti-B-cell lymphoma-2; Bax, Anti-Bcl-2-associated X protein; ALT, Alanine transaminase; GST, Glutathione-s-transferase; NF-&#x003ba;B, Nuclear factor kappa B; CK-NAC, Creatine kinase-NAC; IL-8, Interleukin 8</p></table-wrap-foot></table-wrap>
</p><p id="Par12">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>The characteristics Hesperetin of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Author, year</th><th align="left">Models</th><th align="left">Chemotherapy medications (dosage) &#x00026; Treatment protocol &#x00026; Route of<break/>administration type</th><th align="left">Outcomes of chemotherapy medications on cardiac tissue</th><th align="left">Hesperetin dosage &#x00026; protocol of usage &#x00026; route of administration</th><th align="left">Hesperetin co-administration outcomes</th></tr></thead><tbody><tr><td align="left">Trivedi, P. P., et al., 2011 [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left">In-vivo/ Rat</td><td align="left">Doxorubicin (4&#x000a0;mg/kg bw) &#x00026; once a week for 5 weeks &#x00026; <italic>ip</italic></td><td align="left">&#x02191;Levels of MDA, &#x02191;comet parameters (TL, TM, OTM, &#x00026; % DNA), cell damage, TUNEL-positive cells, &#x02193;Levels of GSH, &#x02191;Expression of NF-&#x003ba;B, p38, &#x00026; Caspase-3. Disorganization of the cellular structure and vacuolization in the heart.</td><td align="left">100&#x000a0;mg/kg bw &#x00026; 5 days a week for 5 weeks &#x00026; <italic>po</italic></td><td align="left">&#x02193;Levels of MDA, &#x02191;Levels of GSH, &#x02193;comet parameters (TL, TM, OTM, &#x00026; % DNA), cell damage, TUNEL-positive cells. &#x02193;Expression of NF-kB, p38, &#x00026; Caspase-3. Decreased damage in the cardiac cellular morphology</td></tr><tr><td align="left">Pop Moldovan, A., et al., 2024 [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left">In-vivo/ mouse</td><td align="left">Epirubicin (2&#x000a0;mg/kg) &#x00026; 6 doses every other day, starting from the second day of the experiment &#x00026; <italic>ip</italic></td><td align="left"><p>&#x02191;Expression of Bax, Caspase-3, &#x02191;TUNEL-positive nuclei, &#x02193;Expression of Bcl-2</p><p>cytoplasmic vacuolization, myofibril loss, and disarray of fibers, inflammatory cell infiltration and a slight increase in interstitial collagen fibers, noticeable disorganization of the intermediate filaments, localized accumulation of lipids and collagen</p></td><td align="left">100&#x000a0;mg/kg &#x00026; 13 consecutive days, starting from the first day of the experiment &#x00026; <italic>po</italic></td><td align="left"><p>&#x02193;Expression of Bax &#x00026; Caspase-3, &#x02191;Expression of Bcl-2.</p><p>&#x02193;TUNEL-positive nuclei, the heart tissue of the group receiving both treatments largely resembled that of the control group.</p></td></tr></tbody></table><table-wrap-foot><p>&#x02191;, Increase; &#x02193;, Decease; &#x00026;, And; <italic>ip</italic>, Intraperitoneal; <italic>po</italic>, Per os; GSH: Glutathione; MDA, Malondialdehyde; Bcl-2, Anti-B-cell lymphoma-2; Bax, Anti-Bcl-2-associated X protein; NF-&#x003ba;B, Nuclear factor kappa B; TL, tail length; TM, tail moment; OTM, olive tail moment</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec9"><title>The role of hesperidin and Hesperetin against cardiotoxicity induced by chemotherapy medications</title><sec id="Sec10"><title>Doxorubicin</title><p id="Par13">Doxorubicin is an anthracycline family employed as a powerful chemotherapeutic medication for the treatment of many malignancies. Nonetheless, its practical application is constrained by associated adverse effects, notably its cardiotoxicity [<xref ref-type="bibr" rid="CR29">29</xref>]. The studies indicated that when doxorubicin was used, the levels of important antioxidants like glutathione peroxidase (GPx), glutathione (GSH), arylesterase (AE), catalase, superoxide dismutase (SOD), and paraoxonase (PON) were lower compared to the normal control group, indicating more oxidative stress. It was discovered that GPx, GSH, AE, catalase, SOD, and PON worked better when hesperidin was taken with doxorubicin compared to when doxorubicin was taken by itself [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>]. Additionally, it was shown that giving doxorubicin led to a significant increase in the activity of nuclear factor kappa B (NF-&#x003ba;B), myeloperoxidase (MPO), p38, and caspase-3, as well as higher levels of oxidized low-density lipoproteins (ox-LDL), nitric oxide (NO), malondialdehyde (MDA), comet assay parameters (OTM, TM, TL, and % DNA), and TUNEL-positive cells compared to the normal control group. When hesperidin and doxorubicin were given together, the levels of MPO, ox-LDL, MDA, and NO, along with the activity of NF-&#x003ba;B, p38, and caspase-3, decreased significantly compared to the doxorubicin group. When hesperidin and doxorubicin were given together induced the levels of MPO, ox-LDL, MDA, and NO as well as activity of NF-&#x003ba;B, p38, and caspase-3 dropped significantly in comparison to the doxorubicin group [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>]. Contrary to the results of other studies, Donia, T., et al. identified elevated catalase activity in the doxorubicin group compared to the normal group which is reduced when co-administered with both hesperidin and doxorubicin [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par14">It was found that giving doxorubicin greatly increased the levels of biomarkers for cardiac injury. Troponin I (cTn-I), troponin T (cTn-T), myosin light-chain kinase I (MYLK), lactate dehydrogenase (LDH), and aspartate aminotransferase (AST) were some of these that were studied. Compared to the normal control group, the doxorubicin group had higher levels of inflammatory markers like tumor necrosis factor &#x003b1; (TNF-&#x003b1;), interleukin 1&#x003b2; (IL-1&#x003b2;), interferon &#x003b3; (IFN-&#x003b3;), and C-reactive protein (CRP). When hesperidin and doxorubicin were given together, they greatly lowered levels of cTn-T, cTn-I, MYLK, LDH, AST, TNF-&#x003b1;, IL-1&#x003b2;, IFN-&#x003b3;, and CRP compared to the doxorubicin group [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par15">High levels of brain natriuretic peptide (BNP) were seen after doxorubicin was given. BNP is a biomarker that shows the heart&#x02019;s ventricular walls were stretching more than in the normal control group. When hesperidin and doxorubicin were given together, the higher BNP levels were restored compared to the doxorubicin group [<xref ref-type="bibr" rid="CR35">35</xref>]. The heart tissue analysis showed that doxorubicin caused the heart to weigh more, increased inflammation, added collagen fibers, caused swelling, severe cell damage, disorganized heart cells, thickened heart muscle, created many small spaces in the cells, made blood vessel walls thicker, and led to too many red blood cells leaving the heart compared to the healthy control group.</p><p id="Par16">When doxorubicin and hesperetin were injected together, they reduced damage to heart cells compared to the group that only got doxorubicin [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>].</p></sec><sec id="Sec11"><title>Paclitaxel</title><p id="Par17">Paclitaxel is a diterpenoid that belongs to the Taxanes group. It is an anticancer drug that is used to treat cancers of the breast, lung, and ovary [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Nonetheless, its practical application is hindered by its cardiotoxicity [<xref ref-type="bibr" rid="CR38">38</xref>]. The study also found a link between paclitaxel induction and cardiac oxidative stress, including elevation of lipid peroxidation (LPO) levels, decreases in GSH level as well as activity of SOD and GPx. When paclitaxel and hesperidin were given together, they dropped the LPO level while raising SOD and GPx activity compared to the paclitaxel group. Moreover, the study&#x02019;s findings show that giving paclitaxel increased heart function biomarkers, including CK-MB and LDH, compared to the healthy control group. Co-administration of paclitaxel with hesperidin significantly decreased the high levels of CK-MB and LDH. The hearts of mice that were given paclitaxel had a lot of hyalinosis and white blood cell infiltration in certain areas. Even so, when paclitaxel and hesperidin were given together, there was no white blood cell infiltration and a lot of hyalinosis became visible [<xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec12"><title>Cisplatin</title><p id="Par18">Cisplatin is an antineoplastic agent based on platinum that is employed to treat multiple cancer types, including testicular, ovarian, head and neck, and lung malignancies [<xref ref-type="bibr" rid="CR40">40</xref>]. Even though cisplatin is widely used and has strong anticancer properties, it has been linked to adverse effects, such as cardiotoxicity [<xref ref-type="bibr" rid="CR41">41</xref>]. It was found that giving cisplatin to animals changed oxidative stress indicators in a big way, including making more thiobarbituric acid reactive substances (TBARS) and MDA. Moreover, there was a remarkable decrease in SOD, GSH, and catalase levels in comparison to the normal control group. The combined treatment of cisplatin and hesperidin brought the high levels of TBARs and MDA back to normal compared to the group that only received cisplatin. Furthermore, studies indicated that people who were given both cisplatin and hesperidin had higher levels of SOD, catalase, and GSH than people who were only given cisplatin [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par19">Cisplatin caused cardiotoxicity, which was linked to significantly higher levels of myocardial biomarkers like troponin I (cTnI), creatine kinase (CK), and LDH, as well as higher levels of inflammatory cytokines like TNF-&#x003b1; and interleukin-6 (IL-6), compared to the healthy control group. Even so, when hesperidin was given along with cisplatin, cardiac markers (cTnI, CK, and LDH) and inflammatory cytokines (TNF-&#x003b1;, IL6) were significantly lowered compared to the cisplatin group [<xref ref-type="bibr" rid="CR43">43</xref>]. While comparing the cisplatin group to the control group, the study&#x02019;s results showed that apoptotic factors like Bax and caspase-3 were turned up and anti-B-cell lymphoma-2 (Bcl-2) was turned down. Conversely, the co-administration of Hesperidin with Cisplatin resulted in a significant down-regulation of Bax and caspase-3 expression, whereas Bcl-2 expression was elevated in comparison to the Cisplatin group. On top of that, compared to the healthy control group, cisplatin-treated mice had much lower levels of signaling pathway proteins like p62 and Nrf2. On the other hand, they had much higher levels of Keap1. On the other hand, the study&#x02019;s results indicated that cisplatin-treated animals had inflammatory cells, apoptotic cells, and edematous cardiac cells in their tissues, while the control group had a normal histological appearance. In animals administered Hesperidin in conjunction with cisplatin, the histological alterations were mitigated [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>].</p></sec><sec id="Sec13"><title>Cyclophosphamide</title><p id="Par20">Cyclophosphamide is a potent antineoplastic agent, classified as an oxazaphosphorine prodrug with alkylating capabilities. It is utilized in the management of a wide array of malignancies and autoimmune disorders [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Cardiotoxicity is an adverse effect linked to cyclophosphamide [<xref ref-type="bibr" rid="CR46">46</xref>]. This research shows that adding cyclophosphamide lowers the amounts of SOD, catalase, GPx, GST, GSH, and TNF-&#x003b1; compared to the healthy control group. In rats administered hesperidin alongside cyclophosphamide, a restoration of elevated levels of these biomarkers was seen.</p><p id="Par21">When cyclophosphamide was given, levels of CK, ALT, AST, LDH, and MDA were all significantly higher than in the control group. When given with cyclophosphamide, hesperidin brought the elevated levels of these markers back to normal [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec14"><title>Epirubicin</title><p id="Par22">Epirubicin is an anthracycline agent that is a 4&#x02032; epimer of doxorubicin and works against different types of cancer [<xref ref-type="bibr" rid="CR49">49</xref>]. Both epirubicin and doxorubicin are linked to cardiotoxicity; however, epirubicin demonstrates less cardiotoxicity [<xref ref-type="bibr" rid="CR50">50</xref>]. The study&#x02019;s findings demonstrated that epirubicin administration led to an increase in Bax expression, a significant rise in caspase-3 immunostaining, and a decrease in Bcl-2 expression, all of which are indicators of apoptosis, compared to the normal control group. Co-administration of epirubicin and hesperetin resulted in decreased levels of Bax and caspase-3, whereas Bcl-2 levels increased in comparison to the epirubicin-only group. The results of the current investigation indicated that epirubicin therapy significantly increased the quantity of TUNEL-positive nuclei compared to the control group. Animals treated with both epirubicin and hesperetin demonstrated a reduced count of positive nuclei relative to those provided with epirubicin alone.</p><p id="Par23">According to the histological data, epirubicin treatment led to more cytoplasmic vacuolization, myofibril loss, fiber disorganization, infiltration of inflammatory cells, minor improvement of interstitial collagen fibers, significant disarray of intermediate filaments, and lower expression of desmin compared to the normal control group [<xref ref-type="bibr" rid="CR51">51</xref>].</p></sec><sec id="Sec15"><title>5-Fluorouracil</title><p id="Par24">5-Fluorouracil (5-FU) is a type of chemotherapy drug that belongs to the pyrimidine analogue group and is commonly used to treat different types of cancer. It inhibits the proliferation of cancer cells by inhibiting DNA and RNA synthesis [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par25">In the Farooq, J., et al. study, it was found that 5-FU led to lower levels of oxidative stress markers SOD, GSH, and catalase compared to the normal control group. However, when hesperidin was given along with 5-FU, there was a significant increase in SOD, GSH, and catalase levels compared to animals that only received 5-FU. While co-administration of hesperidin and 5-FU showed a significant increase in SOD, GSH, and catalase levels compared to animals receiving only 5-FU. Also, 5-FU significantly increased the MPO, MDA, NO, IL-6, IL-8, and TNF-&#x003b1; levels compared to the control group, which is modulated by hesperidin. Furthermore, the levels of cardiac injury markers, including CK-MB, CK-NAC, and LDH, were notably increased by 5-FU treatment as compared to the control group. Concomitant administration of hesperidin and 5-FU led to a significant increase in MB, CK-NAC, and LDH levels compared to the 5-FU group [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par26">In addition, histopathological investigations revealed that 5-FU administration is correlated with vacuolar alternations and necrosis in cardiac tissues of enrolled animals, leading to fragmentation and resembling severe cardiac cell injury compared to the control group. Animals treated with a combination of hesperidin and 5-FU were detected with mild hyperemia in histopathological studies [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par27">The objective of the current investigation was to examine the processes underlying chemotherapy-induced cardiotoxicity and the effects of co-administering these medicines with hesperidin and hesperetin on cardiac function. Evidence indicates that chemotherapy medicines, while beneficial in cancer treatment, are linked to several negative effects across different organs. Cardiovascular adverse effects are particularly significant, as the heart is highly susceptible to these medications, and any cardiac damage may hinder the continuation of treatment [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par28">Hesperidin and its aglycone, hesperetin, are naturally occurring chemicals that are present in several citrus fruits. Both hesperidin and hesperetin are thought to exert therapeutic effects on organs such as the heart and kidneys through several processes [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. This discussion reviews the impact of chemotherapeutic agents on cardiac cells and the functions of hesperidin and hesperetin. Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> illustrates the main mechanisms of chemotherapy-induced cardiotoxicity and the role of hesperidin and hesperetin.</p><p id="Par29">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Mechanisms of chemotherapy-induced cardiotoxicity</p></caption><graphic xlink:href="12935_2025_3828_Fig2_HTML" id="d33e920"/></fig>
</p><p id="Par30">Chemotherapy agents trigger the formation of free radicals, leading to oxidative stress, inflammation, and the initiation of apoptosis. Hesperidin and hesperetin, through their protective properties, mitigate cardiotoxicity induced by chemotherapy agents.</p><p id="Par31">&#x02191;Increased by chemotherapy; &#x02193;Decreased by chemotherapy; phosphorylation (P); superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), reduced glutathione (GSH), oxidised glutathione (GSSG), lipid peroxidation (LPO), malondialdehyde (MDA), thiobarbituric acid reactive substances (TBARs), apoptotic protease activating factor 1 (Apaf-1), cytochrome C (Cyt C), nuclear factor kappa-&#x003b2; (NF-&#x003ba;B), IkappaB (IKB), caspase 3 (Casp-3), Anti-B-cell lymphoma-2 (Bcl-2, ), Anti-Bcl-2-associated X protein (Bax), tumor necrosis factor-alpha (TNF-&#x003b1;), interleukin 6 (IL-6), and interleukin one beta (IL-1&#x003b2;).</p><sec id="Sec17"><title>Anti-oxidant actions</title><p id="Par32">While oxygen is necessary for aerobic respiration in humans, it also helps make compounds called activated oxygen or reactive oxygen species (ROS), which can damage cells&#x02019; functional and structural parts [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Approximately 95% of oxygen is utilized for energy production and ultimately converted into water; however, the remaining 5% generates metabolites known as activated ROS, which exhibit high reactivity. ROS are created when molecular oxygen (O<sub>2</sub>) changes into superoxide anion radicals (O<sub>2</sub>&#x0207b;), hydroxyl radicals (HO&#x0207b;), hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), and other radicals [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Consequently, ROS are standard physiological by-products of cellular metabolic processes, mostly generated by mitochondria [<xref ref-type="bibr" rid="CR59">59</xref>]. Oxidative stress was caused by many physiological and pathological conditions, such as getting older, being active, low oxygen levels, radiation, and drug treatments (like chemotherapy medications) [<xref ref-type="bibr" rid="CR60">60</xref>&#x02013;<xref ref-type="bibr" rid="CR63">63</xref>]. Researchers have found that normal levels of ROS are important for many cellular processes and act as signaling molecules [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. In addition, complex, multi-level antioxidant defense systems work to get rid of ROS or lessen the damage they do [<xref ref-type="bibr" rid="CR66">66</xref>]. The oxidative stress pathway is made up of enzymes and molecules. These include the SOD, GPx, GR, and catalase enzymes, as well as GSH molecules, which are important for the antioxidant defense system [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par33">SOD enzyme serves as the primary defensive mechanism, transforming superoxide radicals into the less harmful hydrogen peroxide. GPx and catalase enzymes collaborate with SOD to decompose hydrogen peroxide in water [<xref ref-type="bibr" rid="CR68">68</xref>&#x02013;<xref ref-type="bibr" rid="CR70">70</xref>]. During oxidative stress, GSH safeguards cells from harm inflicted by free radicals. GPx helps change GSH into glutathione disulfide (GSSG) in the ROS enzyme reaction. This procedure lowers the amounts of both GSH and ROS [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. In addition, LPO is a complex biochemical process in which free radicals, especially ROS, damage lipids inside cell membranes. This results in the oxidative degradation of lipids, yielding lipid peroxides and other detrimental consequences [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par34">Chemotherapeutic medications can elevate ROS levels through three mechanisms: (1) Some chemotherapeutics, like doxorubicin, raise ROS levels by breaking down into unstable radicals. (2) They do this by increasing the activity of pro-oxidative enzymes like NADPH oxidase. (3) They do this by selectively decreasing the activity of cellular antioxidants like SOD [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par35">Hesperidin and hesperetin are powerful antioxidants that work in two main ways: directly (by scavenging free radicals and giving hydrogen to free radicals) and indirectly (by stopping prooxidative enzymes, increasing antioxidant enzymes, protecting mitochondrial function, and improving glutathione redox status) [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. This study indicated that chemotherapy medications led to oxidative stress in the heart by decreasing the activity of SOD, GPx, catalase, and GST enzymes, increasing TBARS and MDA levels, and decreasing GSH levels. These effects were changed by hesperidin and hesperetin, which have antioxidant properties [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec18"><title>Anti-apoptotic actions</title><p id="Par36">Apoptosis is a cautiously controlled process that gets rid of damaged and old cells. It helps keep things in balance and makes room for new, healthy cells [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. During apoptosis, cells&#x02019; structures change in several ways. In these processes, cells get smaller, chromatin condenses, membranes bleb, nuclei fragment (DNA laddering), apoptotic bodies form, and then neighboring cells phagocytize them [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. Research has indicated two primary molecular signaling mechanisms for apoptosis:</p><p id="Par37">
<list list-type="order"><list-item><p id="Par38">Intrinsic (mitochondrial) route; (2) extrinsic (death receptor) pathway [<xref ref-type="bibr" rid="CR81">81</xref>]</p></list-item></list>
</p><p id="Par39">Irradiation, oxidative stress, and treatment with cytotoxic drugs can all create stress inside cells that activate the intrinsic (mitochondrial) pathway. Bak and Bax are proteins belonging to the Bcl-2 family. When they attach to the mitochondrial membrane, it becomes leaky, letting cytochrome c move from the space between the membranes to the cytosol. After that, cytochrome c combines with procaspase-9 and apoptotic protease activating factor 1 (APAF-1) to form the apoptosome that activates caspase-9. Activation of caspase-9 initiates a cascade of caspase activation involving caspase-3, -6, and &#x02212;&#x02009;7. This results in the cleavage of cellular proteins, fragmentation of DNA, and subsequent cell death [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. Extracellular death ligands interact with and turn on death receptors on the target cell&#x02019;s surface to start the extrinsic (death receptor) pathway. These death ligands normally come from other cells, mainly immune cells or nearby cells, with varied goals, such as the eradication of contaminated or cancerous cells. Adaptor proteins, such as FADD (Fas-associated death domain), are utilized to assemble the death-inducing signaling complex (DISC) upon activation of certain death receptors. DISC subsequently activates procaspase-8, transforming it into caspase-8. The activation of caspase-8 initiates a cascade of caspase activations, including caspases 3, 6, and 7. This induces DNA fragmentation, cleavage of cellular proteins, and ultimately results in apoptosis [<xref ref-type="bibr" rid="CR84">84</xref>&#x02013;<xref ref-type="bibr" rid="CR86">86</xref>].</p><p id="Par40">Chemotherapeutic agents can induce apoptosis in cancer cells, which display an unusually high rate of division. Chemotherapy efficiently promotes death in cancer cells; nevertheless, it also affects healthy cells, leading to various side effects and organ damage [<xref ref-type="bibr" rid="CR87">87</xref>&#x02013;<xref ref-type="bibr" rid="CR90">90</xref>]. Chemotherapeutic agents such as doxorubicin induce apoptosis in healthy cardiac cells. This phenomenon occurs in both acute and chronic myocyte loss, ultimately leading to cardiomyopathy [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. Thus, they can induce apoptosis by engaging both intrinsic and extrinsic pathways [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Hesperetin and hesperidin also show significant anti-apoptotic effects, as the current study shows. When you give hesperetin and hesperidin, DNA damage goes down and caspase-3 activity goes up [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. The activity of the NF-&#x003ba;B transcription factor is also decreased when hesperidin and hesperetin are given. This chemical enhances the activity of the Bcl-2 family while diminishing the activity of Bax [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR51">51</xref>].</p></sec><sec id="Sec20"><title>Anti-inflammatory actions</title><p id="Par41">Inflammation is a multifaceted reaction initiated by the immune system to potentially damaging stimuli, including infections, injury, and metabolic stress, to maintain tissue homeostasis [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. The primary characteristics of inflammation encompass erythema, edema, increased temperature, dolor, and impairment of tissue function [<xref ref-type="bibr" rid="CR95">95</xref>]. From a microscopic viewpoint, immune cells trigger an inflammatory response by identifying primary damaging stimuli and, subsequently, activating various intracellular signaling pathways inside the immune cells. The outcome of these pathways&#x02019; activation is the stimulation of transcription factors, including NF-&#x003ba;B and AP-1. Active transcription factors facilitate the expression of inflammatory genes. This produces a diverse array of inflammatory mediators, including cytokines (such as IL-1&#x003b2;, IL-6, IL-10, IFN-&#x003b3;, and TNF-&#x003b1;), chemokines, prostaglandins, and leukotrienes. These mediators bring neutrophils, monocytes, and lymphocytes to the site of the first stimulus, where they kill the first damaging stimuli by phagocytosis or cytotoxicity [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. Nevertheless, these activities may adversely affect healthy cells at the inflammatory site, potentially resulting in significant side effects and organ damage [<xref ref-type="bibr" rid="CR98">98</xref>]. Numerous studies have revealed the chemotherapeutic medication&#x02019;s inflammatory effects on the heart [<xref ref-type="bibr" rid="CR99">99</xref>]. Researchers have found that chemotherapeutic medications induced elevation in levels of IFN-&#x003b3;, TNF-&#x003b1;, IL-6, IL-8, CRP, IL-1&#x003b2;, and Nrf2. This elevation was significantly modified by the administration of hesperidin and hesperetin in the heart [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. In addition, researchers have found that giving hesperidin and hesperetin lowers the activity of pro-inflammatory enzymes like cyclooxygenase-2 (COX-2), which makes prostaglandins. It also obstructs the activation of the NF-&#x003ba;B pathway, leading to the attenuation of inflammation [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR100">100</xref>].</p></sec></sec><sec id="Sec21"><title>The perspective of future research</title><p id="Par42">Chemotherapy is a prevalent cancer treatment globally, utilizing diverse effective cytotoxic medications with distinct modes of action to inhibit cells exhibiting aberrant proliferation and division rates. While chemotherapy significantly extends the lives of cancer patients, it still poses significant challenges to their quality of life. Chemotherapy chemicals can damage healthy cells due to their cytotoxic properties [<xref ref-type="bibr" rid="CR8">8</xref>]. Moreover, the manifestation of these adverse effects can hinder clinicians from persisting with treatment and diminish the efficacy of chemotherapy. Cardiotoxicity is a significant adverse consequence of chemotherapy, presenting in numerous manifestations, such as arrhythmias, alterations in blood pressure, myocarditis, heart failure, and sudden myocardial infarction [<xref ref-type="bibr" rid="CR101">101</xref>]. A randomized controlled trial (RCT) systematic review and meta-analysis research on 525 participants have examined the efficacy of hesperidin for various illnesses. Hesperidin supplements have been shown to lower serum levels of triglycerides, total cholesterol, and low-density lipoprotein. Furthermore, hesperidin lowers TNF-&#x003b1; and blood pressure, which may affect a patient&#x02019;s cardiovascular risk factors [<xref ref-type="bibr" rid="CR102">102</xref>]. Moreover, in another RCT study, hesperidin significantly improved patients with metabolic syndrome and diabetic neuropathy [<xref ref-type="bibr" rid="CR103">103</xref>]. Also, hesperidin reduced systolic blood pressure and tended to lower diastolic blood pressure in type 2 diabetes, according to another RCT systematic review and meta-analysis study that included 656 patients [<xref ref-type="bibr" rid="CR104">104</xref>]. The present study, based on animal and in vitro research, indicates the positive effects of hesperidin and hesperetin on cardiotoxicity induced by chemotherapy. The therapeutic potential of hesperidin and hesperetin in mitigating cardiotoxicity induced by chemotherapy remains inadequately understood and warrants further investigation through rigorously designed clinical trials to elucidate their efficacy and mechanisms of action.</p></sec><sec id="Sec22"><title>Conclusion</title><p id="Par43">This study&#x02019;s findings underscore that cardiotoxicity is among the most perilous adverse effects induced by chemotherapy agents. Chemotherapy adversely affects the heart by generating damaging ROS, initiating apoptosis via several pathways, and inducing inflammation. Hesperidin and hesperetin have been shown to lower the risk of cardiotoxicity when used with chemotherapy medications. This beneficial effect is achieved by alleviating oxidative stress, preventing apoptosis, and modifying the processes that govern inflammation. Based on research that hasn&#x02019;t been done yet, this study suggests that using hesperidin and hesperetin together might improve chemotherapy management. The results highlight the translational potential of these flavonoids, emphasizing the need for thorough preclinical optimization and clinical trials to confirm their efficacy and safety. This review establishes a basis for incorporating natural chemicals into cardioprotective approaches in oncology. Further well-designed clinical trials are necessary to confirm the cardioprotective effects of hesperidin and hesperetin.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Sina Shaernejad and Ali Nosrat have contributed equally to this work as first authors.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Sina Shaernejad: Investigation, Methodology, Writing - original draft, Prepared Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>. Ali Nosrat: Data curation, Investigation, Methodology. Maryam Baeeri: Conceptualization, Writing - original draft, Writing - review &#x00026; editing. Nasser Hashemi Goradel: Investigation, Writing - original draft. Mirsalim SeyedSadeghi: Investigation, Writing - original draft. Mostafa Akbariani: Writing - review &#x00026; editing. AmirAhmad Arabzadeh: Conceptualization, Supervision, Writing - review &#x00026; editing. Mahban Rahimifard: Data curation, Supervision, Writing - original draft, Writing - review &#x00026; editing. Hamed Haghi-Aminjan: Investigation, Writing, - original draft, Writing - review &#x00026; editing. All authors reviewed the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par44">This study has only been a systematic review and no need to ethics approval.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par45">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Harding MC, Sloan CD, Merrill RM, Harding TM, Thacker BJ, Thacker EL. Peer reviewed: transitions from heart disease to cancer as the leading cause of death in US States, 1999&#x02013;2016. Preventing chronic disease. 2018;15.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Weiderpass</surname><given-names>E</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name></person-group><article-title>The ever-increasing importance of cancer as a leading cause of premature death worldwide</article-title><source>Cancer</source><year>2021</year><volume>127</volume><issue>16</issue><fpage>3029</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1002/cncr.33587</pub-id><pub-id pub-id-type="pmid">34086348</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029&#x02013;30.<pub-id pub-id-type="pmid">34086348</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Health topics: cancer. [<ext-link ext-link-type="uri" xlink:href="https://www.who.int/health-topics/cancer#tab=tab_1">https://www.who.int/health-topics/cancer#tab=tab_1</ext-link>]</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229&#x02013;63.<pub-id pub-id-type="pmid">38572751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>HW</given-names></name><name><surname>Fan</surname><given-names>R</given-names></name><name><surname>Zhai</surname><given-names>YS</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>ZB</given-names></name><name><surname>Peng</surname><given-names>LY</given-names></name></person-group><article-title>Incidence of chemotherapy-related cardiac dysfunction in cancer patients</article-title><source>Clin Cardiol</source><year>2024</year><volume>47</volume><issue>4</issue><fpage>e24269</fpage><pub-id pub-id-type="doi">10.1002/clc.24269</pub-id><pub-id pub-id-type="pmid">38634453</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Deng HW, Fan R, Zhai YS, Li J, Huang ZB, Peng LY. Incidence of chemotherapy-related cardiac dysfunction in cancer patients. Clin Cardiol. 2024;47(4):e24269.<pub-id pub-id-type="pmid">38634453</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Debela</surname><given-names>DT</given-names></name><name><surname>Muzazu</surname><given-names>SG</given-names></name><name><surname>Heraro</surname><given-names>KD</given-names></name><name><surname>Ndalama</surname><given-names>MT</given-names></name><name><surname>Mesele</surname><given-names>BW</given-names></name><name><surname>Haile</surname><given-names>DC</given-names></name><name><surname>Kitui</surname><given-names>SK</given-names></name><name><surname>Manyazewal</surname><given-names>T</given-names></name></person-group><article-title>New approaches and procedures for cancer treatment: current perspectives</article-title><source>SAGE Open Med</source><year>2021</year><volume>9</volume><fpage>20503121211034366</fpage><pub-id pub-id-type="doi">10.1177/20503121211034366</pub-id><pub-id pub-id-type="pmid">34408877</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK, Manyazewal T. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med. 2021;9:20503121211034366.<pub-id pub-id-type="pmid">34408877</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Bukowski</surname><given-names>K</given-names></name><name><surname>Kciuk</surname><given-names>M</given-names></name><name><surname>Kontek</surname><given-names>R</given-names></name></person-group><article-title>Mechanisms of multidrug resistance in cancer chemotherapy</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><issue>9</issue><fpage>3233</fpage><pub-id pub-id-type="doi">10.3390/ijms21093233</pub-id><pub-id pub-id-type="pmid">32370233</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233.<pub-id pub-id-type="pmid">32370233</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Brianna</surname><given-names>LSH</given-names></name></person-group><article-title>Chemotherapy: how to reduce its adverse effects while maintaining the potency?</article-title><source>Med Oncol</source><year>2023</year><volume>40</volume><issue>3</issue><fpage>88</fpage><pub-id pub-id-type="doi">10.1007/s12032-023-01954-6</pub-id><pub-id pub-id-type="pmid">36735206</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Brianna LSH. Chemotherapy: how to reduce its adverse effects while maintaining the potency? Med Oncol. 2023;40(3):88.<pub-id pub-id-type="pmid">36735206</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name></person-group><article-title>Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology</article-title><source>Dose-Response</source><year>2020</year><volume>18</volume><issue>3</issue><fpage>1559325820936161</fpage><pub-id pub-id-type="doi">10.1177/1559325820936161</pub-id><pub-id pub-id-type="pmid">32699536</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Yan L, Shen J, Wang J, Yang X, Dong S, Lu S. Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose-Response. 2020;18(3):1559325820936161.<pub-id pub-id-type="pmid">32699536</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>van den Boogaard</surname><given-names>WM</given-names></name><name><surname>Komninos</surname><given-names>DS</given-names></name><name><surname>Vermeij</surname><given-names>WP</given-names></name></person-group><article-title>Chemotherapy side-effects: not all DNA damage is equal</article-title><source>Cancers</source><year>2022</year><volume>14</volume><issue>3</issue><fpage>627</fpage><pub-id pub-id-type="doi">10.3390/cancers14030627</pub-id><pub-id pub-id-type="pmid">35158895</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">van den Boogaard WM, Komninos DS, Vermeij WP. Chemotherapy side-effects: not all DNA damage is equal. Cancers. 2022;14(3):627.<pub-id pub-id-type="pmid">35158895</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Florescu</surname><given-names>M</given-names></name><name><surname>Cinteza</surname><given-names>M</given-names></name><name><surname>Vinereanu</surname><given-names>D</given-names></name></person-group><article-title>Chemotherapy-induced cardiotoxicity</article-title><source>Maedica</source><year>2013</year><volume>8</volume><issue>1</issue><fpage>59</fpage><pub-id pub-id-type="pmid">24023601</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced cardiotoxicity. Maedica. 2013;8(1):59.<pub-id pub-id-type="pmid">24023601</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Schimmel</surname><given-names>KJ</given-names></name><name><surname>Richel</surname><given-names>DJ</given-names></name><name><surname>Van den Brink</surname><given-names>RB</given-names></name><name><surname>Guchelaar</surname><given-names>H-J</given-names></name></person-group><article-title>Cardiotoxicity of cytotoxic drugs</article-title><source>Cancer Treat Rev</source><year>2004</year><volume>30</volume><issue>2</issue><fpage>181</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2003.07.003</pub-id><pub-id pub-id-type="pmid">15023436</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Schimmel KJ, Richel DJ, Van den Brink RB, Guchelaar H-J. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004;30(2):181&#x02013;91.<pub-id pub-id-type="pmid">15023436</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Kalam</surname><given-names>K</given-names></name><name><surname>Marwick</surname><given-names>TH</given-names></name></person-group><article-title>Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis</article-title><source>Eur J Cancer</source><year>2013</year><volume>49</volume><issue>13</issue><fpage>2900</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2013.04.030</pub-id><pub-id pub-id-type="pmid">23706982</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2013;49(13):2900&#x02013;9.<pub-id pub-id-type="pmid">23706982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Salimi A, Asgari B, Khezri S, Pourgholi M, Haddadi S. Hesperidin as a bioactive compound in citrus fruits reduces N-ethyl-N-nitrosourea-induced mortality and toxicity in mice: as a model for chronic lymphocytic leukemia. Naunyn-Schmiedeberg&#x02019;s archives of pharmacology 2024.</mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Shabani</surname><given-names>M</given-names></name><name><surname>Jamali</surname><given-names>Z</given-names></name><name><surname>Bayrami</surname><given-names>D</given-names></name><name><surname>Salimi</surname><given-names>A</given-names></name></person-group><article-title>Hesperidin via maintenance of mitochondrial function and antioxidant activity protects lithium toxicity in rat heart isolated mitochondria</article-title><source>Drug Chem Toxicol</source><year>2024</year><volume>47</volume><issue>5</issue><fpage>597</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1080/01480545.2023.2228521</pub-id><pub-id pub-id-type="pmid">37369581</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Shabani M, Jamali Z, Bayrami D, Salimi A. Hesperidin via maintenance of mitochondrial function and antioxidant activity protects lithium toxicity in rat heart isolated mitochondria. Drug Chem Toxicol. 2024;47(5):597&#x02013;605.<pub-id pub-id-type="pmid">37369581</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Khezri</surname><given-names>S</given-names></name><name><surname>Azizian</surname><given-names>S</given-names></name><name><surname>Salimi</surname><given-names>A</given-names></name></person-group><article-title>Pre-mating exposure with hesperidin protects N-ethyl-N-nitrosourea-induced neurotoxicity and congenital abnormalities in next generation of mice as a model of glioma</article-title><source>J Mol Histol</source><year>2024</year><volume>55</volume><issue>4</issue><fpage>627</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s10735-024-10218-0</pub-id><pub-id pub-id-type="pmid">38916842</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Khezri S, Azizian S, Salimi A. Pre-mating exposure with hesperidin protects N-ethyl-N-nitrosourea-induced neurotoxicity and congenital abnormalities in next generation of mice as a model of glioma. J Mol Histol. 2024;55(4):627&#x02013;36.<pub-id pub-id-type="pmid">38916842</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>A</given-names></name><name><surname>Murakami</surname><given-names>Y</given-names></name><name><surname>Shoji</surname><given-names>M</given-names></name><name><surname>Kadoma</surname><given-names>Y</given-names></name><name><surname>Fujisawa</surname><given-names>S</given-names></name></person-group><article-title>Kinetics of radical-scavenging activity of Hesperetin and hesperidin and their inhibitory activity on COX-2 expression</article-title><source>Anticancer Res</source><year>2005</year><volume>25</volume><issue>5</issue><fpage>3367</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">16101151</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Hirata A, Murakami Y, Shoji M, Kadoma Y, Fujisawa S. Kinetics of radical-scavenging activity of Hesperetin and hesperidin and their inhibitory activity on COX-2 expression. Anticancer Res. 2005;25(5):3367&#x02013;74.<pub-id pub-id-type="pmid">16101151</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Roohbakhsh</surname><given-names>A</given-names></name><name><surname>Parhiz</surname><given-names>H</given-names></name><name><surname>Soltani</surname><given-names>F</given-names></name><name><surname>Rezaee</surname><given-names>R</given-names></name><name><surname>Iranshahi</surname><given-names>M</given-names></name></person-group><article-title>Molecular mechanisms behind the biological effects of hesperidin and Hesperetin for the prevention of cancer and cardiovascular diseases</article-title><source>Life Sci</source><year>2015</year><volume>124</volume><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2014.12.030</pub-id><pub-id pub-id-type="pmid">25625242</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Roohbakhsh A, Parhiz H, Soltani F, Rezaee R, Iranshahi M. Molecular mechanisms behind the biological effects of hesperidin and Hesperetin for the prevention of cancer and cardiovascular diseases. Life Sci. 2015;124:64&#x02013;74.<pub-id pub-id-type="pmid">25625242</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Salimi</surname><given-names>A</given-names></name><name><surname>Khezri</surname><given-names>S</given-names></name><name><surname>Vahabzadeh</surname><given-names>Z</given-names></name><name><surname>Rajabi</surname><given-names>P</given-names></name><name><surname>Samimi</surname><given-names>R</given-names></name><name><surname>Adhami</surname><given-names>V</given-names></name></person-group><article-title>Hesperidin, vanillic acid, and sinapic acid attenuate atorvastatin-induced mitochondrial dysfunction via Inhibition of mitochondrial swelling and maintenance of mitochondrial function in pancreas isolated mitochondria</article-title><source>Drug Dev Res</source><year>2024</year><volume>85</volume><issue>4</issue><fpage>e22199</fpage><pub-id pub-id-type="doi">10.1002/ddr.22199</pub-id><pub-id pub-id-type="pmid">38812443</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Salimi A, Khezri S, Vahabzadeh Z, Rajabi P, Samimi R, Adhami V. Hesperidin, vanillic acid, and sinapic acid attenuate atorvastatin-induced mitochondrial dysfunction via Inhibition of mitochondrial swelling and maintenance of mitochondrial function in pancreas isolated mitochondria. Drug Dev Res. 2024;85(4):e22199.<pub-id pub-id-type="pmid">38812443</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Jamali</surname><given-names>Z</given-names></name><name><surname>Salimi</surname><given-names>A</given-names></name><name><surname>Garmabi</surname><given-names>B</given-names></name><name><surname>Khezri</surname><given-names>S</given-names></name><name><surname>Khaksari</surname><given-names>M</given-names></name></person-group><article-title>Hesperidin protects alcohol-Induced mitochondrial abnormalities via the Inhibition of oxidative stress and MPT pore opening in newborn male rats as a fetal alcohol syndrome model</article-title><source>J Stud Alcohol Drug</source><year>2024</year><volume>85</volume><issue>3</issue><fpage>361</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.15288/jsad.23-00243</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Jamali Z, Salimi A, Garmabi B, Khezri S, Khaksari M. Hesperidin protects alcohol-Induced mitochondrial abnormalities via the Inhibition of oxidative stress and MPT pore opening in newborn male rats as a fetal alcohol syndrome model. J Stud Alcohol Drug. 2024;85(3):361&#x02013;70.</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Ahmed OM, Mahmoud AM, Abdel-Moneim A, Ashour MB. Antidiabetic effects of hesperidin and naringin in type 2 diabetic rats. 2012.</mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Revathy</surname><given-names>J</given-names></name><name><surname>Abdullah</surname><given-names>SS</given-names></name></person-group><article-title>The role of Hesperetin in the management of diabetes mellitus and its complications</article-title><source>J Cancer Treat Res</source><year>2017</year><volume>5</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.11648/j.jctr.20170501.11</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Revathy J, Abdullah SS. The role of Hesperetin in the management of diabetes mellitus and its complications. J Cancer Treat Res. 2017;5(1):1&#x02013;6.</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Mittal</surname><given-names>S</given-names></name><name><surname>Gulia</surname><given-names>R</given-names></name><name><surname>Alam</surname><given-names>K</given-names></name><name><surname>Saha</surname><given-names>TK</given-names></name><name><surname>Arif</surname><given-names>Z</given-names></name><name><surname>Nafees</surname><given-names>K</given-names></name><name><surname>Al-Shaghdali</surname><given-names>K</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name></person-group><article-title>Therapeutic role of hesperidin in collagen&#x02010;induced rheumatoid arthritis through antiglycation and antioxidant activities</article-title><source>Cell Biochem Funct</source><year>2022</year><volume>40</volume><issue>5</issue><fpage>473</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1002/cbf.3708</pub-id><pub-id pub-id-type="pmid">35657316</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ahmad S, Mittal S, Gulia R, Alam K, Saha TK, Arif Z, Nafees K, Al-Shaghdali K, Ahmad S. Therapeutic role of hesperidin in collagen&#x02010;induced rheumatoid arthritis through antiglycation and antioxidant activities. Cell Biochem Funct. 2022;40(5):473&#x02013;80.<pub-id pub-id-type="pmid">35657316</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>EM</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name></person-group><article-title>Effects of Hesperetin on the production of inflammatory mediators in IL-1&#x003b2; treated human synovial cells</article-title><source>Cell Immunol</source><year>2010</year><volume>264</volume><issue>1</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2010.05.006</pub-id><pub-id pub-id-type="pmid">20538267</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Choi EM, Lee YS. Effects of Hesperetin on the production of inflammatory mediators in IL-1&#x003b2; treated human synovial cells. Cell Immunol. 2010;264(1):1&#x02013;3.<pub-id pub-id-type="pmid">20538267</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Salami</surname><given-names>A</given-names></name><name><surname>Seydi</surname><given-names>E</given-names></name><name><surname>Pourahmad</surname><given-names>J</given-names></name></person-group><article-title>Use of nutraceuticals for prevention and treatment of cancer</article-title><source>Iran J Pharm Research: IJPR</source><year>2013</year><volume>12</volume><issue>3</issue><fpage>219</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">24250626</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Salami A, Seydi E, Pourahmad J. Use of nutraceuticals for prevention and treatment of cancer. Iran J Pharm Research: IJPR. 2013;12(3):219&#x02013;20.<pub-id pub-id-type="pmid">24250626</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Ikram</surname><given-names>M</given-names></name><name><surname>Hahm</surname><given-names>JR</given-names></name><name><surname>Kim</surname><given-names>MO</given-names></name></person-group><article-title>Antioxidant and anti-inflammatory effects of citrus flavonoid Hesperetin: special focus on neurological disorders</article-title><source>Antioxidants</source><year>2020</year><volume>9</volume><issue>7</issue><fpage>609</fpage><pub-id pub-id-type="doi">10.3390/antiox9070609</pub-id><pub-id pub-id-type="pmid">32664395</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Khan A, Ikram M, Hahm JR, Kim MO. Antioxidant and anti-inflammatory effects of citrus flavonoid Hesperetin: special focus on neurological disorders. Antioxidants. 2020;9(7):609.<pub-id pub-id-type="pmid">32664395</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>MJ</given-names></name><name><surname>McKenzie</surname><given-names>JE</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Boutron</surname><given-names>I</given-names></name><name><surname>Hoffmann</surname><given-names>TC</given-names></name><name><surname>Mulrow</surname><given-names>CD</given-names></name><name><surname>Shamseer</surname><given-names>L</given-names></name><name><surname>Tetzlaff</surname><given-names>JM</given-names></name><name><surname>Akl</surname><given-names>EA</given-names></name><name><surname>Brennan</surname><given-names>SE</given-names></name><etal/></person-group><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ (Clinical Res ed)</source><year>2021</year><volume>372</volume><fpage>n71</fpage></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n71.</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Bramer</surname><given-names>WM</given-names></name><name><surname>Milic</surname><given-names>J</given-names></name><name><surname>Mast</surname><given-names>F</given-names></name></person-group><article-title>Reviewing retrieved references for inclusion in systematic reviews using endnote</article-title><source>J Med Libr Association: JMLA</source><year>2017</year><volume>105</volume><issue>1</issue><fpage>84</fpage><lpage>7</lpage></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Bramer WM, Milic J, Mast F. Reviewing retrieved references for inclusion in systematic reviews using endnote. J Med Libr Association: JMLA. 2017;105(1):84&#x02013;7.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Moini Jazani</surname><given-names>A</given-names></name><name><surname>Arabzadeh</surname><given-names>A</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Nasimi Doost Azgomi</surname><given-names>R</given-names></name></person-group><article-title>The role of ginseng derivatives against chemotherapy-induced cardiotoxicity: A systematic review of non-clinical studies</article-title><source>Front Cardiovasc Med</source><year>2023</year><volume>10</volume><fpage>1022360</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2023.1022360</pub-id><pub-id pub-id-type="pmid">36844721</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Moini Jazani A, Arabzadeh A, Haghi-Aminjan H, Nasimi Doost Azgomi R. The role of ginseng derivatives against chemotherapy-induced cardiotoxicity: A systematic review of non-clinical studies. Front Cardiovasc Med. 2023;10:1022360.<pub-id pub-id-type="pmid">36844721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Alharbi</surname><given-names>FK</given-names></name><name><surname>Alshehri</surname><given-names>ZS</given-names></name><name><surname>Alshehri</surname><given-names>FF</given-names></name><name><surname>Alhajlah</surname><given-names>S</given-names></name><name><surname>Khalifa</surname><given-names>HA</given-names></name><name><surname>Dahran</surname><given-names>N</given-names></name><name><surname>Ghonimi</surname><given-names>WA</given-names></name></person-group><article-title>The role of hesperidin as a cardioprotective strategy against doxorubicin-induced cardiotoxicity: the antioxidant, anti-inflammatory, antiapoptotic, and cytoprotective potentials</article-title><source>Open Veterinary J</source><year>2023</year><volume>13</volume><issue>12</issue><fpage>1718</fpage><pub-id pub-id-type="doi">10.5455/OVJ.2023.v13.i12.20</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Alharbi FK, Alshehri ZS, Alshehri FF, Alhajlah S, Khalifa HA, Dahran N, Ghonimi WA. The role of hesperidin as a cardioprotective strategy against doxorubicin-induced cardiotoxicity: the antioxidant, anti-inflammatory, antiapoptotic, and cytoprotective potentials. Open Veterinary J. 2023;13(12):1718.</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Donia</surname><given-names>T</given-names></name><name><surname>Eldaly</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>EM</given-names></name></person-group><article-title>Ameliorating oxidative stress and inflammation by hesperidin and vitamin E in doxorubicin induced cardiomyopathy</article-title><source>Turkish J Biochem</source><year>2019</year><volume>44</volume><issue>2</issue><fpage>207</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1515/tjb-2018-0156</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Donia T, Eldaly S, Ali EM. Ameliorating oxidative stress and inflammation by hesperidin and vitamin E in doxorubicin induced cardiomyopathy. Turkish J Biochem. 2019;44(2):207&#x02013;17.</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Farooq J, Sultana R, James JP, Fathima CZ, Almutairy AF, Hussain ASM. Efficacy of thymoquinone and hesperidin in attenuating cardiotoxicity from 5-Fluorouracil: insights from in vivo and in Silico studies. Toxics 2024;12(9).</mixed-citation></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Saad</surname><given-names>S</given-names></name><name><surname>Ahmad</surname><given-names>I</given-names></name><name><surname>Kawish</surname><given-names>SM</given-names></name><name><surname>Khan</surname><given-names>UA</given-names></name><name><surname>Ahmad</surname><given-names>FJ</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Jain</surname><given-names>GK</given-names></name></person-group><article-title>Improved cardioprotective effects of hesperidin solid lipid nanoparticles prepared by supercritical antisolvent technology</article-title><source>Colloids Surf B Biointerfaces</source><year>2020</year><volume>187</volume><fpage>110628</fpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2019.110628</pub-id><pub-id pub-id-type="pmid">31753617</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Saad S, Ahmad I, Kawish SM, Khan UA, Ahmad FJ, Ali A, Jain GK. Improved cardioprotective effects of hesperidin solid lipid nanoparticles prepared by supercritical antisolvent technology. Colloids Surf B Biointerfaces. 2020;187:110628.<pub-id pub-id-type="pmid">31753617</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>P</given-names></name><name><surname>Kushwaha</surname><given-names>S</given-names></name><name><surname>Tripathi</surname><given-names>D</given-names></name><name><surname>Jena</surname><given-names>G</given-names></name></person-group><article-title>Cardioprotective effects of Hesperetin against doxorubicin-induced oxidative stress and DNA damage in rat</article-title><source>Cardiovasc Toxicol</source><year>2011</year><volume>11</volume><issue>3</issue><fpage>215</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/s12012-011-9114-2</pub-id><pub-id pub-id-type="pmid">21553131</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Trivedi P, Kushwaha S, Tripathi D, Jena G. Cardioprotective effects of Hesperetin against doxorubicin-induced oxidative stress and DNA damage in rat. Cardiovasc Toxicol. 2011;11(3):215&#x02013;25.<pub-id pub-id-type="pmid">21553131</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Sefri</surname><given-names>HA</given-names></name><name><surname>Al-Bishri</surname><given-names>WM</given-names></name><name><surname>Hamza</surname><given-names>AM</given-names></name></person-group><article-title>Cardiotherapeutic effect of naringin and hesperidin via Anti-Inflammatory and antioxidant effect in experimental model</article-title><source>Int J Pharm Res Allied Sci</source><year>2020</year><volume>9</volume><issue>4&#x02013;2020</issue><fpage>102</fpage><lpage>12</lpage></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Al-Sefri HA, Al-Bishri WM, Hamza AM. Cardiotherapeutic effect of naringin and hesperidin via Anti-Inflammatory and antioxidant effect in experimental model. Int J Pharm Res Allied Sci. 2020;9(4&#x02013;2020):102&#x02013;12.</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Tong Y, Luo YF, Gao W. Biosynthesis of Paclitaxel using synthetic biology. Phytochem Rev 2021;1&#x02013;15.</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>M-S</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X-Y</given-names></name><name><surname>Chen</surname><given-names>J-S</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>F-F</given-names></name><name><surname>Xue</surname><given-names>L-J</given-names></name></person-group><article-title>Regulatory MicroRNAs and phasirnas of Paclitaxel biosynthesis in Taxus chinensis</article-title><source>Front Plant Sci</source><year>2024</year><volume>15</volume><fpage>1403060</fpage><pub-id pub-id-type="doi">10.3389/fpls.2024.1403060</pub-id><pub-id pub-id-type="pmid">38779066</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Sun M-S, Jia Y, Chen X-Y, Chen J-S, Guo Y, Fu F-F, Xue L-J. Regulatory MicroRNAs and phasirnas of Paclitaxel biosynthesis in Taxus chinensis. Front Plant Sci. 2024;15:1403060.<pub-id pub-id-type="pmid">38779066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Osman</surname><given-names>M</given-names></name><name><surname>Elkady</surname><given-names>M</given-names></name></person-group><article-title>A prospective study to evaluate the effect of Paclitaxel on cardiac ejection fraction</article-title><source>Breast Care</source><year>2017</year><volume>12</volume><issue>4</issue><fpage>255</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1159/000471759</pub-id><pub-id pub-id-type="pmid">29070990</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Osman M, Elkady M. A prospective study to evaluate the effect of Paclitaxel on cardiac ejection fraction. Breast Care. 2017;12(4):255&#x02013;9.<pub-id pub-id-type="pmid">29070990</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>YA</given-names></name><name><surname>Ahmed</surname><given-names>OM</given-names></name><name><surname>Soliman</surname><given-names>HA</given-names></name><name><surname>Abdel-Gabbar</surname><given-names>M</given-names></name><name><surname>Al-Dossari</surname><given-names>M</given-names></name><name><surname>El-Gawaad</surname><given-names>NA</given-names></name><name><surname>El-Nahass</surname><given-names>E-S</given-names></name><name><surname>Ahmed</surname><given-names>NA</given-names></name></person-group><article-title>Rutin and hesperidin alleviate paclitaxel-induced nephrocardiotoxicity in Wistar rats via suppressing the oxidative stress and enhancing the antioxidant defense mechanisms</article-title><source>Evidence&#x02010;based Complement Altern Med</source><year>2023</year><volume>2023</volume><issue>1</issue><fpage>5068304</fpage><pub-id pub-id-type="doi">10.1155/2023/5068304</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Ali YA, Ahmed OM, Soliman HA, Abdel-Gabbar M, Al-Dossari M, El-Gawaad NA, El-Nahass E-S, Ahmed NA. Rutin and hesperidin alleviate paclitaxel-induced nephrocardiotoxicity in Wistar rats via suppressing the oxidative stress and enhancing the antioxidant defense mechanisms. Evidence&#x02010;based Complement Altern Med. 2023;2023(1):5068304.</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Rahimifard</surname><given-names>M</given-names></name><name><surname>Baeeri</surname><given-names>M</given-names></name><name><surname>Mousavi</surname><given-names>T</given-names></name><name><surname>Azarnezhad</surname><given-names>A</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name></person-group><article-title>Combination therapy of cisplatin and Resveratrol to induce cellular aging in gastric cancer cells: focusing on oxidative stress, and cell cycle arrest</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>1068863</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.1068863</pub-id><pub-id pub-id-type="pmid">36686661</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Rahimifard M, Baeeri M, Mousavi T, Azarnezhad A, Haghi-Aminjan H, Abdollahi M. Combination therapy of cisplatin and Resveratrol to induce cellular aging in gastric cancer cells: focusing on oxidative stress, and cell cycle arrest. Front Pharmacol. 2022;13:1068863.<pub-id pub-id-type="pmid">36686661</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>El-Awady</surname><given-names>E-SE</given-names></name><name><surname>Moustafa</surname><given-names>YM</given-names></name><name><surname>Abo-Elmatty</surname><given-names>DM</given-names></name><name><surname>Radwan</surname><given-names>A</given-names></name></person-group><article-title>Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies</article-title><source>Eur J Pharmacol</source><year>2011</year><volume>650</volume><issue>1</issue><fpage>335</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2010.09.085</pub-id><pub-id pub-id-type="pmid">21034734</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">El-Awady E-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies. Eur J Pharmacol. 2011;650(1):335&#x02013;41.<pub-id pub-id-type="pmid">21034734</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Oguzturk</surname><given-names>H</given-names></name><name><surname>Ciftci</surname><given-names>O</given-names></name><name><surname>Cetin</surname><given-names>A</given-names></name><name><surname>Kaya</surname><given-names>K</given-names></name><name><surname>Disli</surname><given-names>OM</given-names></name><name><surname>Turtay</surname><given-names>MG</given-names></name><name><surname>G&#x000fc;rb&#x000fc;z</surname><given-names>S</given-names></name><name><surname>Basak</surname><given-names>N</given-names></name></person-group><article-title>Beneficial effects of hesperidin following cis-diamminedichloroplatinum-induced damage in heart of rats</article-title><source>Niger J Clin Pract</source><year>2016</year><volume>19</volume><issue>1</issue><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.4103/1119-3077.173707</pub-id><pub-id pub-id-type="pmid">26755226</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Oguzturk H, Ciftci O, Cetin A, Kaya K, Disli OM, Turtay MG, G&#x000fc;rb&#x000fc;z S, Basak N. Beneficial effects of hesperidin following cis-diamminedichloroplatinum-induced damage in heart of rats. Niger J Clin Pract. 2016;19(1):99&#x02013;103.<pub-id pub-id-type="pmid">26755226</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Si</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name></person-group><article-title>Hesperidin protects against cisplatin-induced cardiotoxicity in mice by regulating the p62&#x02013;Keap1&#x02013;Nrf2 pathway</article-title><source>Food Funct</source><year>2022</year><volume>13</volume><issue>7</issue><fpage>4205</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1039/D2FO00298A</pub-id><pub-id pub-id-type="pmid">35332348</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Jia Y, Guo H, Cheng X, Zhang Y, Si M, Shi J, Ma D. Hesperidin protects against cisplatin-induced cardiotoxicity in mice by regulating the p62&#x02013;Keap1&#x02013;Nrf2 pathway. Food Funct. 2022;13(7):4205&#x02013;15.<pub-id pub-id-type="pmid">35332348</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Teles</surname><given-names>KA</given-names></name><name><surname>Medeiros-Souza</surname><given-names>P</given-names></name><name><surname>Lima</surname><given-names>FAC</given-names></name><name><surname>Ara&#x000fa;jo BGd, Lima</surname><given-names>RAC</given-names></name></person-group><article-title>Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review</article-title><source>Revista Brasileira De Reumatologia</source><year>2017</year><volume>57</volume><issue>6</issue><fpage>596</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/j.rbr.2016.04.009</pub-id><pub-id pub-id-type="pmid">29173694</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Teles KA, Medeiros-Souza P, Lima FAC, Ara&#x000fa;jo BGd, Lima RAC. Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review. Revista Brasileira De Reumatologia. 2017;57(6):596&#x02013;604.<pub-id pub-id-type="pmid">29173694</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Habibi</surname><given-names>E</given-names></name><name><surname>Shokrzadeh</surname><given-names>M</given-names></name><name><surname>Ahmadi</surname><given-names>A</given-names></name><name><surname>Chabra</surname><given-names>A</given-names></name><name><surname>Naghshvar</surname><given-names>F</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Salehi</surname><given-names>F</given-names></name></person-group><article-title>Pulmonoprotective action of Zataria multiflora ethanolic extract on Cyclophosphamide-Induced oxidative lung toxicity in mice</article-title><source>Chin J Integr Med</source><year>2020</year><volume>26</volume><issue>10</issue><fpage>754</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1007/s11655-018-2984-4</pub-id><pub-id pub-id-type="pmid">30242592</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Habibi E, Shokrzadeh M, Ahmadi A, Chabra A, Naghshvar F, Haghi-Aminjan H, Salehi F. Pulmonoprotective action of Zataria multiflora ethanolic extract on Cyclophosphamide-Induced oxidative lung toxicity in mice. Chin J Integr Med. 2020;26(10):754&#x02013;61.<pub-id pub-id-type="pmid">30242592</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Kamel</surname><given-names>SS</given-names></name><name><surname>Abdelbaky</surname><given-names>NA</given-names></name><name><surname>Sayed-Ahmed</surname><given-names>MM</given-names></name><name><surname>Karkeet</surname><given-names>RM</given-names></name><name><surname>Osman</surname><given-names>A-MM</given-names></name><name><surname>Fouad</surname><given-names>MA</given-names></name></person-group><article-title>Cyclophosphamide-induced cardiotoxicity</article-title><source>Azhar Int J Pharm Med Sci</source><year>2022</year><volume>2</volume><issue>2</issue><fpage>1</fpage><lpage>8</lpage></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Kamel SS, Abdelbaky NA, Sayed-Ahmed MM, Karkeet RM, Osman A-MM, Fouad MA. Cyclophosphamide-induced cardiotoxicity. Azhar Int J Pharm Med Sci. 2022;2(2):1&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Dhankhar</surname><given-names>N</given-names></name><name><surname>Kar</surname><given-names>V</given-names></name><name><surname>Shrivastava</surname><given-names>M</given-names></name><name><surname>Shrivastava</surname><given-names>S</given-names></name></person-group><article-title>Myocardial injury provoked by cyclophosphamide, protective aspect of hesperidin in rats</article-title><source>Int J Res Pharm Biomed Sci</source><year>2011</year><volume>2</volume><issue>3</issue><fpage>1288</fpage><lpage>96</lpage></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Kumar S, Dhankhar N, Kar V, Shrivastava M, Shrivastava S. Myocardial injury provoked by cyclophosphamide, protective aspect of hesperidin in rats. Int J Res Pharm Biomed Sci. 2011;2(3):1288&#x02013;96.</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Shrivastava</surname><given-names>M</given-names></name><name><surname>Kar</surname><given-names>V</given-names></name><name><surname>Shrivastava</surname><given-names>S</given-names></name></person-group><article-title>Cyclophosphamide altered the myocardial marker enzymes: protection provoked by hesperidin in rats</article-title><source>Int J Phytomedicine</source><year>2013</year><volume>5</volume><issue>2</issue><fpage>141</fpage></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Shrivastava M, Kar V, Shrivastava S. Cyclophosphamide altered the myocardial marker enzymes: protection provoked by hesperidin in rats. Int J Phytomedicine. 2013;5(2):141.</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Plosker</surname><given-names>GL</given-names></name><name><surname>Faulds</surname><given-names>D</given-names></name></person-group><article-title>Epirubicin: a review of its pharmacodynamic and Pharmacokinetic properties, and therapeutic use in cancer chemotherapy</article-title><source>Drugs</source><year>1993</year><volume>45</volume><issue>5</issue><fpage>788</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.2165/00003495-199345050-00011</pub-id><pub-id pub-id-type="pmid">7686469</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Plosker GL, Faulds D. Epirubicin: a review of its pharmacodynamic and Pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs. 1993;45(5):788&#x02013;856.<pub-id pub-id-type="pmid">7686469</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaklamani</surname><given-names>VG</given-names></name><name><surname>Gradishar</surname><given-names>WJ</given-names></name></person-group><article-title>Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?</article-title><source>Clin Breast Cancer</source><year>2003</year><volume>4</volume><fpage>S26</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.3816/CBC.2003.s.012</pub-id><pub-id pub-id-type="pmid">12756076</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer. 2003;4:S26&#x02013;33.<pub-id pub-id-type="pmid">12756076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Pop Moldovan</surname><given-names>A</given-names></name><name><surname>Dumitra</surname><given-names>S</given-names></name><name><surname>Popescu</surname><given-names>C</given-names></name><name><surname>Lala</surname><given-names>R</given-names></name><name><surname>Anghel</surname><given-names>NZ</given-names></name><name><surname>Nisulescu</surname><given-names>D</given-names></name><name><surname>Nicoras</surname><given-names>A</given-names></name><name><surname>Cotoraci</surname><given-names>C</given-names></name><name><surname>Puticiu</surname><given-names>M</given-names></name><name><surname>Hermenean</surname><given-names>A</given-names></name></person-group><article-title>Protective effects of Hesperetin on cardiomyocyte integrity and cytoskeletal stability in a murine model of Epirubicin-Induced cardiotoxicity: A histopathological study</article-title><source>Appl Sci</source><year>2024</year><volume>14</volume><issue>6</issue><fpage>2560</fpage><pub-id pub-id-type="doi">10.3390/app14062560</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Pop Moldovan A, Dumitra S, Popescu C, Lala R, Anghel NZ, Nisulescu D, Nicoras A, Cotoraci C, Puticiu M, Hermenean A. Protective effects of Hesperetin on cardiomyocyte integrity and cytoskeletal stability in a murine model of Epirubicin-Induced cardiotoxicity: A histopathological study. Appl Sci. 2024;14(6):2560.</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Sara</surname><given-names>JD</given-names></name><name><surname>Kaur</surname><given-names>J</given-names></name><name><surname>Khodadadi</surname><given-names>R</given-names></name><name><surname>Rehman</surname><given-names>M</given-names></name><name><surname>Lobo</surname><given-names>R</given-names></name><name><surname>Chakrabarti</surname><given-names>S</given-names></name><name><surname>Herrmann</surname><given-names>J</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name></person-group><article-title>5-fluorouracil and cardiotoxicity: a review</article-title><source>Ther Adv Med Oncol</source><year>2018</year><volume>10</volume><fpage>1758835918780140</fpage><pub-id pub-id-type="doi">10.1177/1758835918780140</pub-id><pub-id pub-id-type="pmid">29977352</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, Herrmann J, Lerman A, Grothey A. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140.<pub-id pub-id-type="pmid">29977352</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Monsuez</surname><given-names>J-J</given-names></name><name><surname>Charniot</surname><given-names>J-C</given-names></name><name><surname>Vignat</surname><given-names>N</given-names></name><name><surname>Artigou</surname><given-names>J-Y</given-names></name></person-group><article-title>Cardiac side-effects of cancer chemotherapy</article-title><source>Int J Cardiol</source><year>2010</year><volume>144</volume><issue>1</issue><fpage>3</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2010.03.003</pub-id><pub-id pub-id-type="pmid">20399520</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Monsuez J-J, Charniot J-C, Vignat N, Artigou J-Y. Cardiac side-effects of cancer chemotherapy. Int J Cardiol. 2010;144(1):3&#x02013;15.<pub-id pub-id-type="pmid">20399520</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Caglayan</surname><given-names>C</given-names></name><name><surname>Kandemir</surname><given-names>FM</given-names></name><name><surname>Darendelio&#x0011f;lu</surname><given-names>E</given-names></name><name><surname>K&#x000fc;&#x000e7;&#x000fc;kler</surname><given-names>S</given-names></name><name><surname>Ayna</surname><given-names>A</given-names></name></person-group><article-title>Hesperidin protects liver and kidney against sodium fluoride-induced toxicity through anti-apoptotic and anti-autophagic mechanisms</article-title><source>Life Sci</source><year>2021</year><volume>281</volume><fpage>119730</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2021.119730</pub-id><pub-id pub-id-type="pmid">34147482</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Caglayan C, Kandemir FM, Darendelio&#x0011f;lu E, K&#x000fc;&#x000e7;&#x000fc;kler S, Ayna A. Hesperidin protects liver and kidney against sodium fluoride-induced toxicity through anti-apoptotic and anti-autophagic mechanisms. Life Sci. 2021;281:119730.<pub-id pub-id-type="pmid">34147482</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Asghari</surname><given-names>MH</given-names></name><name><surname>Goharbari</surname><given-names>MH</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name></person-group><article-title>A systematic review on potential mechanisms of Minocycline in kidney diseases</article-title><source>Pharmacol Rep</source><year>2017</year><volume>69</volume><issue>4</issue><fpage>602</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.pharep.2017.02.001</pub-id><pub-id pub-id-type="pmid">28500967</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Haghi-Aminjan H, Asghari MH, Goharbari MH, Abdollahi M. A systematic review on potential mechanisms of Minocycline in kidney diseases. Pharmacol Rep. 2017;69(4):602&#x02013;9.<pub-id pub-id-type="pmid">28500967</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Salimi</surname><given-names>A</given-names></name><name><surname>Motallebi</surname><given-names>A</given-names></name><name><surname>Ayatollahi</surname><given-names>M</given-names></name><name><surname>Seydi</surname><given-names>E</given-names></name><name><surname>Mohseni</surname><given-names>AR</given-names></name><name><surname>Nazemi</surname><given-names>M</given-names></name><name><surname>Pourahmad</surname><given-names>J</given-names></name></person-group><article-title>Selective toxicity of Persian Gulf sea cucumber holothuria parva on human chronic lymphocytic leukemia B lymphocytes by direct mitochondrial targeting</article-title><source>Environ Toxicol</source><year>2017</year><volume>32</volume><issue>4</issue><fpage>1158</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1002/tox.22312</pub-id><pub-id pub-id-type="pmid">27404045</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Salimi A, Motallebi A, Ayatollahi M, Seydi E, Mohseni AR, Nazemi M, Pourahmad J. Selective toxicity of Persian Gulf sea cucumber holothuria parva on human chronic lymphocytic leukemia B lymphocytes by direct mitochondrial targeting. Environ Toxicol. 2017;32(4):1158&#x02013;69.<pub-id pub-id-type="pmid">27404045</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Nakai K, Tsuruta D. What are reactive oxygen species, free radicals, and oxidative stress in skin diseases?? Int J Mol Sci 2021;22(19).</mixed-citation></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Rahimifard</surname><given-names>M</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Hadjighassem</surname><given-names>M</given-names></name><name><surname>Pourahmad Jaktaji</surname><given-names>R</given-names></name><name><surname>Bagheri</surname><given-names>Z</given-names></name><name><surname>Azami Movahed</surname><given-names>M</given-names></name><name><surname>Zarghi</surname><given-names>A</given-names></name><name><surname>Pourahmad</surname><given-names>J</given-names></name></person-group><article-title>Assessment of cytotoxic effects of new derivatives of pyrazino[1,2-a] benzimidazole on isolated human glioblastoma cells and mitochondria</article-title><source>Life Sci</source><year>2021</year><volume>286</volume><fpage>120022</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2021.120022</pub-id><pub-id pub-id-type="pmid">34626606</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Rahimifard M, Haghi-Aminjan H, Hadjighassem M, Pourahmad Jaktaji R, Bagheri Z, Azami Movahed M, Zarghi A, Pourahmad J. Assessment of cytotoxic effects of new derivatives of pyrazino[1,2-a] benzimidazole on isolated human glioblastoma cells and mitochondria. Life Sci. 2021;286:120022.<pub-id pub-id-type="pmid">34626606</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Bardaweel</surname><given-names>SK</given-names></name><name><surname>Gul</surname><given-names>M</given-names></name><name><surname>Alzweiri</surname><given-names>M</given-names></name><name><surname>Ishaqat</surname><given-names>A</given-names></name><name><surname>HA</surname><given-names>AL</given-names></name><name><surname>Bashatwah</surname><given-names>RM</given-names></name></person-group><article-title>Reactive oxygen species: the dual role in physiological and pathological conditions of the human body</article-title><source>Eurasian J Med</source><year>2018</year><volume>50</volume><issue>3</issue><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.5152/eurasianjmed.2018.17397</pub-id><pub-id pub-id-type="pmid">30515042</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Bardaweel SK, Gul M, Alzweiri M, Ishaqat A, HA AL, Bashatwah RM. Reactive oxygen species: the dual role in physiological and pathological conditions of the human body. Eurasian J Med. 2018;50(3):193&#x02013;201.<pub-id pub-id-type="pmid">30515042</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Kara A, Gedikli S, Sengul E, Gelen V, Ozkanlar S. Oxidative Stress and Autophagy. In.; 2016.</mixed-citation></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Momtaz</surname><given-names>S</given-names></name><name><surname>Baeeri</surname><given-names>M</given-names></name><name><surname>Rahimifard</surname><given-names>M</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Hassani</surname><given-names>S</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name></person-group><article-title>Manipulation of molecular pathways and senescence hallmarks by natural compounds in fibroblast cells</article-title><source>J Cell Biochem</source><year>2019</year><volume>120</volume><issue>4</issue><fpage>6209</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/jcb.27909</pub-id><pub-id pub-id-type="pmid">30474871</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Momtaz S, Baeeri M, Rahimifard M, Haghi-Aminjan H, Hassani S, Abdollahi M. Manipulation of molecular pathways and senescence hallmarks by natural compounds in fibroblast cells. J Cell Biochem. 2019;120(4):6209&#x02013;22.<pub-id pub-id-type="pmid">30474871</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Conklin</surname><given-names>KA</given-names></name></person-group><article-title>Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness</article-title><source>Integr cancer Ther</source><year>2004</year><volume>3</volume><issue>4</issue><fpage>294</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1177/1534735404270335</pub-id><pub-id pub-id-type="pmid">15523100</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr cancer Ther. 2004;3(4):294&#x02013;300.<pub-id pub-id-type="pmid">15523100</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Rahimifard M, Baeeri M, Haghi-Aminjan H, Abdollahi M. Unveiling the protective role of Metformin against chemotherapyinduced cardiotoxicity: A comprehensive scoping review on nonclinical studies. Current medicinal chemistry; 2024.</mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Haghi Aminjan</surname><given-names>H</given-names></name><name><surname>Abtahi</surname><given-names>SR</given-names></name><name><surname>Hazrati</surname><given-names>E</given-names></name><name><surname>Chamanara</surname><given-names>M</given-names></name><name><surname>Jalili</surname><given-names>M</given-names></name><name><surname>Paknejad</surname><given-names>B</given-names></name></person-group><article-title>Targeting of oxidative stress and inflammation through ROS/NF-kappaB pathway in phosphine-induced hepatotoxicity mitigation</article-title><source>Life Sci</source><year>2019</year><volume>232</volume><fpage>116607</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2019.116607</pub-id><pub-id pub-id-type="pmid">31254582</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Haghi Aminjan H, Abtahi SR, Hazrati E, Chamanara M, Jalili M, Paknejad B. Targeting of oxidative stress and inflammation through ROS/NF-kappaB pathway in phosphine-induced hepatotoxicity mitigation. Life Sci. 2019;232:116607.<pub-id pub-id-type="pmid">31254582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Najafi</surname><given-names>M</given-names></name><name><surname>Hooshangi Shayesteh</surname><given-names>MR</given-names></name><name><surname>Mortezaee</surname><given-names>K</given-names></name><name><surname>Farhood</surname><given-names>B</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name></person-group><article-title>The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review</article-title><source>Life Sci</source><year>2020</year><volume>241</volume><fpage>117173</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2019.117173</pub-id><pub-id pub-id-type="pmid">31843530</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Najafi M, Hooshangi Shayesteh MR, Mortezaee K, Farhood B, Haghi-Aminjan H. The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review. Life Sci. 2020;241:117173.<pub-id pub-id-type="pmid">31843530</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Lushchak</surname><given-names>VI</given-names></name></person-group><article-title>Free radicals, reactive oxygen species, oxidative stress and its classification</article-title><source>Chemico-Biol Interact</source><year>2014</year><volume>224</volume><fpage>164</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2014.10.016</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Lushchak VI. Free radicals, reactive oxygen species, oxidative stress and its classification. Chemico-Biol Interact. 2014;224:164&#x02013;75.</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Mat&#x000e9;s</surname><given-names>JM</given-names></name><name><surname>P&#x000e9;rez-G&#x000f3;mez</surname><given-names>C</given-names></name><name><surname>De Castro</surname><given-names>IN</given-names></name></person-group><article-title>Antioxidant enzymes and human diseases</article-title><source>Clin Biochem</source><year>1999</year><volume>32</volume><issue>8</issue><fpage>595</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1016/S0009-9120(99)00075-2</pub-id><pub-id pub-id-type="pmid">10638941</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Mat&#x000e9;s JM, P&#x000e9;rez-G&#x000f3;mez C, De Castro IN. Antioxidant enzymes and human diseases. Clin Biochem. 1999;32(8):595&#x02013;603.<pub-id pub-id-type="pmid">10638941</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Branicky</surname><given-names>R</given-names></name><name><surname>No&#x000eb;</surname><given-names>A</given-names></name><name><surname>Hekimi</surname><given-names>S</given-names></name></person-group><article-title>Superoxide dismutases: dual roles in controlling ROS damage and regulating ROS signaling</article-title><source>J Cell Biol</source><year>2018</year><volume>217</volume><issue>6</issue><fpage>1915</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1083/jcb.201708007</pub-id><pub-id pub-id-type="pmid">29669742</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Wang Y, Branicky R, No&#x000eb; A, Hekimi S. Superoxide dismutases: dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol. 2018;217(6):1915&#x02013;28.<pub-id pub-id-type="pmid">29669742</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Hua</surname><given-names>Y</given-names></name></person-group><article-title>Research progress of glutathione peroxidase family (GPX) in redoxidation</article-title><source>Front Pharmacol</source><year>2023</year><volume>14</volume><fpage>1147414</fpage><pub-id pub-id-type="doi">10.3389/fphar.2023.1147414</pub-id><pub-id pub-id-type="pmid">36937839</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Pei J, Pan X, Wei G, Hua Y. Research progress of glutathione peroxidase family (GPX) in redoxidation. Front Pharmacol. 2023;14:1147414.<pub-id pub-id-type="pmid">36937839</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Glorieux</surname><given-names>C</given-names></name><name><surname>Calderon</surname><given-names>PB</given-names></name></person-group><article-title>Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach</article-title><source>Biol Chem</source><year>2017</year><volume>398</volume><issue>10</issue><fpage>1095</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1515/hsz-2017-0131</pub-id><pub-id pub-id-type="pmid">28384098</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Glorieux C, Calderon PB. Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach. Biol Chem. 2017;398(10):1095&#x02013;108.<pub-id pub-id-type="pmid">28384098</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Lubos</surname><given-names>E</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name><name><surname>Handy</surname><given-names>DE</given-names></name></person-group><article-title>Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities</article-title><source>Antioxid Redox Signal</source><year>2011</year><volume>15</volume><issue>7</issue><fpage>1957</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1089/ars.2010.3586</pub-id><pub-id pub-id-type="pmid">21087145</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Lubos E, Loscalzo J, Handy DE. Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2011;15(7):1957&#x02013;97.<pub-id pub-id-type="pmid">21087145</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Lupton</surname><given-names>JR</given-names></name><name><surname>Turner</surname><given-names>ND</given-names></name><name><surname>Fang</surname><given-names>Y-Z</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group><article-title>Glutathione metabolism and its implications for health</article-title><source>J Nutr</source><year>2004</year><volume>134</volume><issue>3</issue><fpage>489</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1093/jn/134.3.489</pub-id><pub-id pub-id-type="pmid">14988435</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Wu G, Lupton JR, Turner ND, Fang Y-Z, Yang S. Glutathione metabolism and its implications for health. J Nutr. 2004;134(3):489&#x02013;92.<pub-id pub-id-type="pmid">14988435</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Mylonas</surname><given-names>C</given-names></name><name><surname>Kouretas</surname><given-names>D</given-names></name></person-group><article-title>Lipid peroxidation and tissue damage</article-title><source>In Vivo (Athens Greece)</source><year>1999</year><volume>13</volume><issue>3</issue><fpage>295</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">10459507</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Mylonas C, Kouretas D. Lipid peroxidation and tissue damage. In Vivo (Athens Greece). 1999;13(3):295&#x02013;309.<pub-id pub-id-type="pmid">10459507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Nizami</surname><given-names>ZN</given-names></name><name><surname>Aburawi</surname><given-names>HE</given-names></name><name><surname>Semlali</surname><given-names>A</given-names></name><name><surname>Muhammad</surname><given-names>K</given-names></name><name><surname>Iratni</surname><given-names>R</given-names></name></person-group><article-title>Oxidative stress inducers in cancer therapy: preclinical and clinical evidence</article-title><source>Antioxidants</source><year>2023</year><volume>12</volume><issue>6</issue><fpage>1159</fpage><pub-id pub-id-type="doi">10.3390/antiox12061159</pub-id><pub-id pub-id-type="pmid">37371889</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Nizami ZN, Aburawi HE, Semlali A, Muhammad K, Iratni R. Oxidative stress inducers in cancer therapy: preclinical and clinical evidence. Antioxidants. 2023;12(6):1159.<pub-id pub-id-type="pmid">37371889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="other">Pyrzynska K. Hesperidin: A review on extraction methods, stability and biological activities. Nutrients 2022;14(12).</mixed-citation></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilmsen</surname><given-names>PK</given-names></name><name><surname>Spada</surname><given-names>DS</given-names></name><name><surname>Salvador</surname><given-names>M</given-names></name></person-group><article-title>Antioxidant activity of the flavonoid hesperidin in chemical and biological systems</article-title><source>J Agric Food Chem</source><year>2005</year><volume>53</volume><issue>12</issue><fpage>4757</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1021/jf0502000</pub-id><pub-id pub-id-type="pmid">15941311</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Wilmsen PK, Spada DS, Salvador M. Antioxidant activity of the flavonoid hesperidin in chemical and biological systems. J Agric Food Chem. 2005;53(12):4757&#x02013;61.<pub-id pub-id-type="pmid">15941311</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Shayesteh</surname><given-names>MRH</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Mousavi</surname><given-names>MJ</given-names></name><name><surname>Momtaz</surname><given-names>S</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name></person-group><article-title>The protective mechanism of Cannabidiol in cardiac injury: A systematic review of Non-Clinical studies</article-title><source>Curr Pharm Design</source><year>2019</year><volume>25</volume><issue>22</issue><fpage>2499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.2174/2210327909666190710103103</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Shayesteh MRH, Haghi-Aminjan H, Mousavi MJ, Momtaz S, Abdollahi M. The protective mechanism of Cannabidiol in cardiac injury: A systematic review of Non-Clinical studies. Curr Pharm Design. 2019;25(22):2499&#x02013;507.</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Rahimifard</surname><given-names>M</given-names></name><name><surname>Bagheri</surname><given-names>Z</given-names></name><name><surname>Hadjighassem</surname><given-names>M</given-names></name><name><surname>Jaktaji</surname><given-names>RP</given-names></name><name><surname>Behroodi</surname><given-names>E</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Movahed</surname><given-names>MA</given-names></name><name><surname>Latifi</surname><given-names>H</given-names></name><name><surname>Hosseindoost</surname><given-names>S</given-names></name><name><surname>Zarghi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Investigation of anti-cancer effects of new pyrazino[1,2-a]benzimidazole derivatives on human glioblastoma cells through 2D in vitro model and 3D-printed microfluidic device</article-title><source>Life Sci</source><year>2022</year><volume>302</volume><fpage>120505</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2022.120505</pub-id><pub-id pub-id-type="pmid">35358594</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Rahimifard M, Bagheri Z, Hadjighassem M, Jaktaji RP, Behroodi E, Haghi-Aminjan H, Movahed MA, Latifi H, Hosseindoost S, Zarghi A, et al. Investigation of anti-cancer effects of new pyrazino[1,2-a]benzimidazole derivatives on human glioblastoma cells through 2D in vitro model and 3D-printed microfluidic device. Life Sci. 2022;302:120505.<pub-id pub-id-type="pmid">35358594</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Lawen</surname><given-names>A</given-names></name></person-group><article-title>Apoptosis&#x02014;an introduction</article-title><source>BioEssays</source><year>2003</year><volume>25</volume><issue>9</issue><fpage>888</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1002/bies.10329</pub-id><pub-id pub-id-type="pmid">12938178</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Lawen A. Apoptosis&#x02014;an introduction. BioEssays. 2003;25(9):888&#x02013;96.<pub-id pub-id-type="pmid">12938178</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>KC</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name></person-group><article-title>How cells die: apoptosis pathways</article-title><source>J Allergy Clin Immunol</source><year>2001</year><volume>108</volume><issue>4</issue><fpage>S99</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1067/mai.2001.117819</pub-id><pub-id pub-id-type="pmid">11586274</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Zimmermann KC, Green DR. How cells die: apoptosis pathways. J Allergy Clin Immunol. 2001;108(4):S99&#x02013;103.<pub-id pub-id-type="pmid">11586274</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Ashkenazi</surname><given-names>A</given-names></name></person-group><article-title>Targeting the extrinsic apoptosis pathway in cancer</article-title><source>Cytokine Growth Factor Rev</source><year>2008</year><volume>19</volume><issue>3&#x02013;4</issue><fpage>325</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2008.04.001</pub-id><pub-id pub-id-type="pmid">18495520</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008;19(3&#x02013;4):325&#x02013;31.<pub-id pub-id-type="pmid">18495520</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C-C</given-names></name><name><surname>Bratton</surname><given-names>SB</given-names></name></person-group><article-title>Regulation of the intrinsic apoptosis pathway by reactive oxygen species</article-title><source>Antioxid Redox Signal</source><year>2013</year><volume>19</volume><issue>6</issue><fpage>546</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1089/ars.2012.4905</pub-id><pub-id pub-id-type="pmid">22978471</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Wu C-C, Bratton SB. Regulation of the intrinsic apoptosis pathway by reactive oxygen species. Antioxid Redox Signal. 2013;19(6):546&#x02013;58.<pub-id pub-id-type="pmid">22978471</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Jan</surname><given-names>R</given-names></name></person-group><article-title>Understanding apoptosis and apoptotic pathways targeted cancer therapeutics</article-title><source>Adv Pharm Bull</source><year>2019</year><volume>9</volume><issue>2</issue><fpage>205</fpage><pub-id pub-id-type="doi">10.15171/apb.2019.024</pub-id><pub-id pub-id-type="pmid">31380246</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Jan R. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull. 2019;9(2):205.<pub-id pub-id-type="pmid">31380246</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Ashkenazi</surname><given-names>A</given-names></name></person-group><article-title>Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions</article-title><source>J Clin Investig</source><year>2015</year><volume>125</volume><issue>2</issue><fpage>487</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1172/JCI80420</pub-id><pub-id pub-id-type="pmid">25642709</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Ashkenazi A. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J Clin Investig. 2015;125(2):487&#x02013;9.<pub-id pub-id-type="pmid">25642709</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S</given-names></name><name><surname>Debatin</surname><given-names>K-M</given-names></name></person-group><article-title>Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><issue>34</issue><fpage>4798</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209608</pub-id><pub-id pub-id-type="pmid">16892092</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Fulda S, Debatin K-M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25(34):4798&#x02013;811.<pub-id pub-id-type="pmid">16892092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Lossi</surname><given-names>L</given-names></name></person-group><article-title>The concept of intrinsic versus extrinsic apoptosis</article-title><source>Biochem J</source><year>2022</year><volume>479</volume><issue>3</issue><fpage>357</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1042/BCJ20210854</pub-id><pub-id pub-id-type="pmid">35147165</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Lossi L. The concept of intrinsic versus extrinsic apoptosis. Biochem J. 2022;479(3):357&#x02013;84.<pub-id pub-id-type="pmid">35147165</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Hannun</surname><given-names>YA</given-names></name></person-group><article-title>Apoptosis and the dilemma of cancer chemotherapy</article-title><source>Blood J Am Soc Hematol</source><year>1997</year><volume>89</volume><issue>6</issue><fpage>1845</fpage><lpage>53</lpage></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood J Am Soc Hematol. 1997;89(6):1845&#x02013;53.</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Asghari</surname><given-names>MH</given-names></name><name><surname>Farhood</surname><given-names>B</given-names></name><name><surname>Rahimifard</surname><given-names>M</given-names></name><name><surname>Hashemi Goradel</surname><given-names>N</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name></person-group><article-title>The role of melatonin on chemotherapy-induced reproductive toxicity</article-title><source>J Pharm Pharmacol</source><year>2018</year><volume>70</volume><issue>3</issue><fpage>291</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1111/jphp.12855</pub-id><pub-id pub-id-type="pmid">29168173</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Haghi-Aminjan H, Asghari MH, Farhood B, Rahimifard M, Hashemi Goradel N, Abdollahi M. The role of melatonin on chemotherapy-induced reproductive toxicity. J Pharm Pharmacol. 2018;70(3):291&#x02013;306.<pub-id pub-id-type="pmid">29168173</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Farhood</surname><given-names>B</given-names></name><name><surname>Rahimifard</surname><given-names>M</given-names></name><name><surname>Didari</surname><given-names>T</given-names></name><name><surname>Baeeri</surname><given-names>M</given-names></name><name><surname>Hassani</surname><given-names>S</given-names></name><name><surname>Hosseini</surname><given-names>R</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name></person-group><article-title>The protective role of melatonin in chemotherapy-induced nephrotoxicity: a systematic review of non-clinical studies</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2018</year><volume>14</volume><issue>9</issue><fpage>937</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1080/17425255.2018.1513492</pub-id><pub-id pub-id-type="pmid">30118646</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Haghi-Aminjan H, Farhood B, Rahimifard M, Didari T, Baeeri M, Hassani S, Hosseini R, Abdollahi M. The protective role of melatonin in chemotherapy-induced nephrotoxicity: a systematic review of non-clinical studies. Expert Opin Drug Metab Toxicol. 2018;14(9):937&#x02013;50.<pub-id pub-id-type="pmid">30118646</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Mortezaee</surname><given-names>K</given-names></name><name><surname>Ahmadi</surname><given-names>A</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Khanlarkhani</surname><given-names>N</given-names></name><name><surname>Salehi</surname><given-names>E</given-names></name><name><surname>Shabani Nashtaei</surname><given-names>M</given-names></name><name><surname>Farhood</surname><given-names>B</given-names></name><name><surname>Najafi</surname><given-names>M</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name></person-group><article-title>Thyroid function following breast cancer chemotherapy: A systematic review</article-title><source>J Cell Biochem</source><year>2019</year><volume>120</volume><issue>8</issue><fpage>12101</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/jcb.28771</pub-id><pub-id pub-id-type="pmid">31021464</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Mortezaee K, Ahmadi A, Haghi-Aminjan H, Khanlarkhani N, Salehi E, Shabani Nashtaei M, Farhood B, Najafi M, Sahebkar A. Thyroid function following breast cancer chemotherapy: A systematic review. J Cell Biochem. 2019;120(8):12101&#x02013;7.<pub-id pub-id-type="pmid">31021464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Kalyanaraman</surname><given-names>B</given-names></name><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Kalivendi</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Konorev</surname><given-names>E</given-names></name><name><surname>Kotamraju</surname><given-names>S</given-names></name></person-group><article-title>Doxorubicin-induced apoptosis: implications in cardiotoxicity</article-title><source>Mol Cell Biochem</source><year>2002</year><volume>234</volume><fpage>119</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1023/A:1015976430790</pub-id><pub-id pub-id-type="pmid">12162424</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem. 2002;234:119&#x02013;24.<pub-id pub-id-type="pmid">12162424</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Arola</surname><given-names>OJ</given-names></name><name><surname>Saraste</surname><given-names>A</given-names></name><name><surname>Pulkki</surname><given-names>K</given-names></name><name><surname>Kallajoki</surname><given-names>M</given-names></name><name><surname>Parvinen</surname><given-names>M</given-names></name><name><surname>Voipio-Pulkki</surname><given-names>L-M</given-names></name></person-group><article-title>Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><issue>7</issue><fpage>1789</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">10766158</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki L-M. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000;60(7):1789&#x02013;92.<pub-id pub-id-type="pmid">10766158</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Kushner</surname><given-names>I</given-names></name></person-group><article-title>It&#x02019;s time to redefine inflammation</article-title><source>FASEB J</source><year>2017</year><volume>31</volume><issue>5</issue><fpage>1787</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1096/fj.201601326R</pub-id><pub-id pub-id-type="pmid">28179421</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Antonelli M, Kushner I. It&#x02019;s time to redefine inflammation. FASEB J. 2017;31(5):1787&#x02013;91.<pub-id pub-id-type="pmid">28179421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Ismail Hassan</surname><given-names>F</given-names></name><name><surname>Didari</surname><given-names>T</given-names></name><name><surname>Baeeri</surname><given-names>M</given-names></name><name><surname>Gholami</surname><given-names>M</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Khalid</surname><given-names>M</given-names></name><name><surname>Navaei-Nigjeh</surname><given-names>M</given-names></name><name><surname>Rahimifard</surname><given-names>M</given-names></name><name><surname>Solgi</surname><given-names>S</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metformin attenuates brain injury by inhibiting inflammation and regulating tight junction proteins in septic rats</article-title><source>Cell J</source><year>2020</year><volume>22</volume><issue>Suppl 1</issue><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">32779431</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Ismail Hassan F, Didari T, Baeeri M, Gholami M, Haghi-Aminjan H, Khalid M, Navaei-Nigjeh M, Rahimifard M, Solgi S, Abdollahi M, et al. Metformin attenuates brain injury by inhibiting inflammation and regulating tight junction proteins in septic rats. Cell J. 2020;22(Suppl 1):29&#x02013;37.<pub-id pub-id-type="pmid">32779431</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>Pattern recognition receptors and inflammation</article-title><source>Cell</source><year>2010</year><volume>140</volume><issue>6</issue><fpage>805</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.01.022</pub-id><pub-id pub-id-type="pmid">20303872</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805&#x02013;20.<pub-id pub-id-type="pmid">20303872</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name></person-group><article-title>Inflammatory responses and inflammation-associated diseases in organs</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><issue>6</issue><fpage>7204</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.23208</pub-id><pub-id pub-id-type="pmid">29467962</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204.<pub-id pub-id-type="pmid">29467962</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Farhadi</surname><given-names>R</given-names></name><name><surname>Daniali</surname><given-names>M</given-names></name><name><surname>Baeeri</surname><given-names>M</given-names></name><name><surname>Foroumadi</surname><given-names>R</given-names></name><name><surname>Gholami</surname><given-names>M</given-names></name><name><surname>Hassani</surname><given-names>S</given-names></name><name><surname>Mirzababaei</surname><given-names>S</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Navaei-Nigjeh</surname><given-names>M</given-names></name><name><surname>Rahimifard</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metformin ameliorates cardiopulmonary toxicity induced by Chlorpyrifos</article-title><source>Drug Chem Toxicol</source><year>2024</year><volume>47</volume><issue>5</issue><fpage>649</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1080/01480545.2023.2239523</pub-id><pub-id pub-id-type="pmid">37501618</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Farhadi R, Daniali M, Baeeri M, Foroumadi R, Gholami M, Hassani S, Mirzababaei S, Haghi-Aminjan H, Navaei-Nigjeh M, Rahimifard M, et al. Metformin ameliorates cardiopulmonary toxicity induced by Chlorpyrifos. Drug Chem Toxicol. 2024;47(5):649&#x02013;61.<pub-id pub-id-type="pmid">37501618</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>AU</given-names></name></person-group><article-title>An overview of inflammation: mechanism and consequences</article-title><source>Front Biology</source><year>2011</year><volume>6</volume><issue>4</issue><fpage>274</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1007/s11515-011-1123-9</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Ahmed AU. An overview of inflammation: mechanism and consequences. Front Biology. 2011;6(4):274&#x02013;81.</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Tejada</surname><given-names>S</given-names></name><name><surname>Pinya</surname><given-names>S</given-names></name><name><surname>Martorell</surname><given-names>M</given-names></name><name><surname>Cap&#x000f3;</surname><given-names>X</given-names></name><name><surname>Tur</surname><given-names>JA</given-names></name><name><surname>Pons</surname><given-names>A</given-names></name><name><surname>Sureda</surname><given-names>A</given-names></name></person-group><article-title>Potential anti-inflammatory effects of hesperidin from the genus citrus</article-title><source>Curr Med Chem</source><year>2018</year><volume>25</volume><issue>37</issue><fpage>4929</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.2174/0929867324666170718104412</pub-id><pub-id pub-id-type="pmid">28721824</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Tejada S, Pinya S, Martorell M, Cap&#x000f3; X, Tur JA, Pons A, Sureda A. Potential anti-inflammatory effects of hesperidin from the genus citrus. Curr Med Chem. 2018;25(37):4929&#x02013;45.<pub-id pub-id-type="pmid">28721824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Parhiz</surname><given-names>H</given-names></name><name><surname>Roohbakhsh</surname><given-names>A</given-names></name><name><surname>Soltani</surname><given-names>F</given-names></name><name><surname>Rezaee</surname><given-names>R</given-names></name><name><surname>Iranshahi</surname><given-names>M</given-names></name></person-group><article-title>Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and Hesperetin: an updated review of their molecular mechanisms and experimental models</article-title><source>Phytother Res</source><year>2015</year><volume>29</volume><issue>3</issue><fpage>323</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/ptr.5256</pub-id><pub-id pub-id-type="pmid">25394264</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Parhiz H, Roohbakhsh A, Soltani F, Rezaee R, Iranshahi M. Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and Hesperetin: an updated review of their molecular mechanisms and experimental models. Phytother Res. 2015;29(3):323&#x02013;31.<pub-id pub-id-type="pmid">25394264</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Samadi</surname><given-names>M</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><name><surname>Sattari</surname><given-names>M</given-names></name><name><surname>Hooshangi Shayesteh</surname><given-names>MR</given-names></name><name><surname>Bameri</surname><given-names>B</given-names></name><name><surname>Armandeh</surname><given-names>M</given-names></name><name><surname>Naddafi</surname><given-names>M</given-names></name><name><surname>Eghbal</surname><given-names>MA</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name></person-group><article-title>The role of taurine on chemotherapy-induced cardiotoxicity: A systematic review of non-clinical study</article-title><source>Life Sci</source><year>2021</year><volume>265</volume><fpage>118813</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118813</pub-id><pub-id pub-id-type="pmid">33275984</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Samadi M, Haghi-Aminjan H, Sattari M, Hooshangi Shayesteh MR, Bameri B, Armandeh M, Naddafi M, Eghbal MA, Abdollahi M. The role of taurine on chemotherapy-induced cardiotoxicity: A systematic review of non-clinical study. Life Sci. 2021;265:118813.<pub-id pub-id-type="pmid">33275984</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Khorasanian</surname><given-names>AS</given-names></name><name><surname>Fateh</surname><given-names>ST</given-names></name><name><surname>Gholami</surname><given-names>F</given-names></name><name><surname>Rasaei</surname><given-names>N</given-names></name><name><surname>Gerami</surname><given-names>H</given-names></name><name><surname>Khayyatzadeh</surname><given-names>SS</given-names></name><name><surname>Shiraseb</surname><given-names>F</given-names></name><name><surname>Asbaghi</surname><given-names>O</given-names></name></person-group><article-title>The effects of hesperidin supplementation on cardiovascular risk factors in adults: a systematic review and dose&#x02013;response meta-analysis</article-title><source>Front Nutr</source><year>2023</year><volume>10</volume><fpage>1177708</fpage><pub-id pub-id-type="doi">10.3389/fnut.2023.1177708</pub-id><pub-id pub-id-type="pmid">37502716</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Khorasanian AS, Fateh ST, Gholami F, Rasaei N, Gerami H, Khayyatzadeh SS, Shiraseb F, Asbaghi O. The effects of hesperidin supplementation on cardiovascular risk factors in adults: a systematic review and dose&#x02013;response meta-analysis. Front Nutr. 2023;10:1177708.<pub-id pub-id-type="pmid">37502716</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Osama</surname><given-names>H</given-names></name><name><surname>Hamed</surname><given-names>EO</given-names></name><name><surname>Mahmoud</surname><given-names>MA</given-names></name><name><surname>Abdelrahim</surname><given-names>MEA</given-names></name></person-group><article-title>The effect of hesperidin and diosmin individually or in combination on metabolic profile and neuropathy among diabetic patients with metabolic syndrome: A randomized controlled trial</article-title><source>J Diet Supplements</source><year>2023</year><volume>20</volume><issue>5</issue><fpage>749</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1080/19390211.2022.2107138</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Osama H, Hamed EO, Mahmoud MA, Abdelrahim MEA. The effect of hesperidin and diosmin individually or in combination on metabolic profile and neuropathy among diabetic patients with metabolic syndrome: A randomized controlled trial. J Diet Supplements. 2023;20(5):749&#x02013;62.</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Hesperidin reduces systolic blood pressure in diabetic patients and has no effect on blood pressure in healthy individuals: A systematic review and meta-analysis</article-title><source>Phytother Res</source><year>2024</year><volume>38</volume><issue>7</issue><fpage>3706</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1002/ptr.8231</pub-id><pub-id pub-id-type="pmid">38772688</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Gao H, Chen F, Wang S. Hesperidin reduces systolic blood pressure in diabetic patients and has no effect on blood pressure in healthy individuals: A systematic review and meta-analysis. Phytother Res. 2024;38(7):3706&#x02013;19.<pub-id pub-id-type="pmid">38772688</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>